JP2000515114A - キナゾリン誘導体 - Google Patents
キナゾリン誘導体Info
- Publication number
- JP2000515114A JP2000515114A JP09522568A JP52256897A JP2000515114A JP 2000515114 A JP2000515114 A JP 2000515114A JP 09522568 A JP09522568 A JP 09522568A JP 52256897 A JP52256897 A JP 52256897A JP 2000515114 A JP2000515114 A JP 2000515114A
- Authority
- JP
- Japan
- Prior art keywords
- methoxy
- quinazoline
- chloro
- mmol
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title claims abstract description 7
- -1 cyano, amino Chemical group 0.000 claims abstract description 313
- 150000001875 compounds Chemical class 0.000 claims abstract description 179
- 150000003839 salts Chemical class 0.000 claims abstract description 92
- 239000001257 hydrogen Substances 0.000 claims abstract description 91
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 91
- 238000000034 method Methods 0.000 claims abstract description 71
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 50
- 230000008569 process Effects 0.000 claims abstract description 32
- 230000000694 effects Effects 0.000 claims abstract description 26
- 125000005843 halogen group Chemical group 0.000 claims abstract description 26
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 22
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 11
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims abstract description 8
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 197
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims description 55
- 150000002431 hydrogen Chemical class 0.000 claims description 54
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 40
- 238000006243 chemical reaction Methods 0.000 claims description 37
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 32
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 32
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 150000003246 quinazolines Chemical class 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 15
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 230000008728 vascular permeability Effects 0.000 claims description 11
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 10
- 125000001153 fluoro group Chemical group F* 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 229940100198 alkylating agent Drugs 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 4
- 230000003527 anti-angiogenesis Effects 0.000 claims description 4
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 125000001425 triazolyl group Chemical group 0.000 claims description 4
- RPEWRZHZDKCHAS-UHFFFAOYSA-N 4-fluoro-5-(6-methoxy-7-phenylmethoxyquinazolin-4-yl)oxy-2-methylphenol Chemical compound N1=CN=C2C=C(OCC=3C=CC=CC=3)C(OC)=CC2=C1OC1=CC(O)=C(C)C=C1F RPEWRZHZDKCHAS-UHFFFAOYSA-N 0.000 claims description 3
- JAUULSWVLCBTNE-UHFFFAOYSA-N ClC1=CC(=C(NC2=NC=NC3=CC(=C(C=C23)OC)OCCN2C=CC(C=C2)=O)C=C1)F.ClC1=CC(=C(NC2=NC=NC3=CC(=C(C=C23)OC)OCCOC2=CC=NC=C2)C=C1)F Chemical compound ClC1=CC(=C(NC2=NC=NC3=CC(=C(C=C23)OC)OCCN2C=CC(C=C2)=O)C=C1)F.ClC1=CC(=C(NC2=NC=NC3=CC(=C(C=C23)OC)OCCOC2=CC=NC=C2)C=C1)F JAUULSWVLCBTNE-UHFFFAOYSA-N 0.000 claims description 3
- 241001024304 Mino Species 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- HXFKORYWVZYGRC-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-(2-pyridin-2-yloxyethoxy)quinazolin-4-amine Chemical compound N1=CN=C2C=C(OCCOC=3N=CC=CC=3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F HXFKORYWVZYGRC-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- RLELBWLVWSGXMA-UHFFFAOYSA-N 4-fluoro-5-[[6-methoxy-7-(2-pyridin-4-ylethoxy)quinazolin-4-yl]amino]-2-methylphenol Chemical compound N1=CN=C2C=C(OCCC=3C=CN=CC=3)C(OC)=CC2=C1NC1=CC(O)=C(C)C=C1F RLELBWLVWSGXMA-UHFFFAOYSA-N 0.000 claims description 2
- CKYOIUOEFJABQM-UHFFFAOYSA-N 5-[[6-methoxy-7-(pyridin-2-ylmethoxy)quinazolin-4-yl]amino]-2-methylphenol;5-[[6-methoxy-7-(pyridin-4-ylmethoxy)quinazolin-4-yl]amino]-2-methylphenol Chemical compound N1=CN=C2C=C(OCC=3C=CN=CC=3)C(OC)=CC2=C1NC1=CC=C(C)C(O)=C1.N1=CN=C2C=C(OCC=3N=CC=CC=3)C(OC)=CC2=C1NC1=CC=C(C)C(O)=C1 CKYOIUOEFJABQM-UHFFFAOYSA-N 0.000 claims description 2
- PIUHOZHDXUZWSN-UHFFFAOYSA-N 5-[[6-methoxy-7-(pyridin-3-ylmethoxy)quinazolin-4-yl]amino]-2-methylphenol;5-[[6-methoxy-7-(thiophen-3-ylmethoxy)quinazolin-4-yl]amino]-2-methylphenol Chemical compound N1=CN=C2C=C(OCC3=CSC=C3)C(OC)=CC2=C1NC1=CC=C(C)C(O)=C1.N1=CN=C2C=C(OCC=3C=NC=CC=3)C(OC)=CC2=C1NC1=CC=C(C)C(O)=C1 PIUHOZHDXUZWSN-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- GVVDIHOYJPJAON-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-(2-pyridin-3-yloxyethoxy)quinazolin-4-amine Chemical compound N1=CN=C2C=C(OCCOC=3C=NC=CC=3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F GVVDIHOYJPJAON-UHFFFAOYSA-N 0.000 claims description 2
- LBIOYXLVKZXBHX-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-7-(2-imidazol-1-ylethoxy)-6-methoxyquinazolin-4-amine Chemical compound N1=CN=C2C=C(OCCN3C=NC=C3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F LBIOYXLVKZXBHX-UHFFFAOYSA-N 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 19
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract description 17
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract description 17
- 206010028980 Neoplasm Diseases 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 201000011510 cancer Diseases 0.000 abstract description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 499
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 474
- 239000000203 mixture Substances 0.000 description 340
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 305
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 285
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 158
- 239000000243 solution Substances 0.000 description 157
- 239000007787 solid Substances 0.000 description 156
- 238000001914 filtration Methods 0.000 description 154
- 239000007858 starting material Substances 0.000 description 151
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 131
- 238000001704 evaporation Methods 0.000 description 129
- 230000008020 evaporation Effects 0.000 description 129
- 239000002904 solvent Substances 0.000 description 129
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 119
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 105
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 104
- 238000000921 elemental analysis Methods 0.000 description 99
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 81
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 64
- 238000004440 column chromatography Methods 0.000 description 58
- 229960004592 isopropanol Drugs 0.000 description 58
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 56
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 54
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 54
- 239000003039 volatile agent Substances 0.000 description 51
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 47
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 45
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 42
- 239000000284 extract Substances 0.000 description 41
- 239000002244 precipitate Substances 0.000 description 40
- 239000012267 brine Substances 0.000 description 39
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 39
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 37
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 37
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 37
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 37
- 235000019441 ethanol Nutrition 0.000 description 36
- 238000010992 reflux Methods 0.000 description 36
- 239000012044 organic layer Substances 0.000 description 33
- 229910000027 potassium carbonate Inorganic materials 0.000 description 32
- 239000011541 reaction mixture Substances 0.000 description 32
- 239000000047 product Substances 0.000 description 31
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
- 239000000725 suspension Substances 0.000 description 30
- VBUBADWLHFZFDK-UHFFFAOYSA-N quinazoline;hydrochloride Chemical compound Cl.N1=CN=CC2=CC=CC=C21 VBUBADWLHFZFDK-UHFFFAOYSA-N 0.000 description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- 239000000706 filtrate Substances 0.000 description 25
- 239000000126 substance Substances 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- XGZKSSTZBKFZMF-UHFFFAOYSA-N 4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-ol Chemical compound N1=CN=C2C=C(O)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F XGZKSSTZBKFZMF-UHFFFAOYSA-N 0.000 description 23
- 239000003054 catalyst Substances 0.000 description 22
- 239000012265 solid product Substances 0.000 description 21
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 18
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 16
- 238000004587 chromatography analysis Methods 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 13
- 239000002585 base Substances 0.000 description 13
- 229960001701 chloroform Drugs 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 238000002844 melting Methods 0.000 description 12
- 230000008018 melting Effects 0.000 description 12
- 239000012312 sodium hydride Substances 0.000 description 12
- 229910000104 sodium hydride Inorganic materials 0.000 description 12
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 239000003701 inert diluent Substances 0.000 description 11
- 239000012442 inert solvent Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 10
- 125000004848 alkoxyethyl group Chemical group 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 239000002198 insoluble material Substances 0.000 description 10
- 239000002480 mineral oil Substances 0.000 description 10
- 235000010446 mineral oil Nutrition 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- OQJBFFCUFALWQL-UHFFFAOYSA-N n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)N=NC(=O)N1CCCCC1 OQJBFFCUFALWQL-UHFFFAOYSA-N 0.000 description 9
- 239000003208 petroleum Substances 0.000 description 9
- 229910052698 phosphorus Inorganic materials 0.000 description 9
- 239000011574 phosphorus Substances 0.000 description 9
- 239000000377 silicon dioxide Substances 0.000 description 9
- 230000009466 transformation Effects 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229940050176 methyl chloride Drugs 0.000 description 8
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 8
- 239000012264 purified product Substances 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 8
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 7
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000033115 angiogenesis Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 102000001301 EGF receptor Human genes 0.000 description 6
- 108060006698 EGF receptor Proteins 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 239000005909 Kieselgur Substances 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 6
- 229940022663 acetate Drugs 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003610 charcoal Substances 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- 239000011591 potassium Substances 0.000 description 6
- 238000007363 ring formation reaction Methods 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 5
- CSFDTBRRIBJILD-UHFFFAOYSA-N 4-chloro-2-fluoroaniline Chemical compound NC1=CC=C(Cl)C=C1F CSFDTBRRIBJILD-UHFFFAOYSA-N 0.000 description 5
- KEMWNYKFWBNOAT-UHFFFAOYSA-N 7-phenylmethoxy-1h-quinazolin-4-one Chemical compound C=1C=C2C(=O)NC=NC2=CC=1OCC1=CC=CC=C1 KEMWNYKFWBNOAT-UHFFFAOYSA-N 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 5
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 241000701447 unidentified baculovirus Species 0.000 description 5
- 210000004291 uterus Anatomy 0.000 description 5
- UDDVPFLXGOBESH-UHFFFAOYSA-N (2-chloropyridin-4-yl)methanol Chemical compound OCC1=CC=NC(Cl)=C1 UDDVPFLXGOBESH-UHFFFAOYSA-N 0.000 description 4
- CLVALLQETQTQMV-UHFFFAOYSA-N 2-(1,2,4-triazol-1-yl)ethanol Chemical compound OCCN1C=NC=N1 CLVALLQETQTQMV-UHFFFAOYSA-N 0.000 description 4
- AROGQTWAAJTEFR-UHFFFAOYSA-N 4-(chloromethyl)pyrimidine Chemical compound ClCC1=CC=NC=N1 AROGQTWAAJTEFR-UHFFFAOYSA-N 0.000 description 4
- HEAQOCBITATQEW-UHFFFAOYSA-N 5-amino-4-fluoro-2-methylphenol Chemical compound CC1=CC(F)=C(N)C=C1O HEAQOCBITATQEW-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000013067 intermediate product Substances 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- LDCYUGVJPXIRCQ-UHFFFAOYSA-N (5-amino-2-methylphenyl) acetate Chemical compound CC(=O)OC1=CC(N)=CC=C1C LDCYUGVJPXIRCQ-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- GCUOLJOTJRUDIZ-UHFFFAOYSA-N 2-(2-bromoethoxy)oxane Chemical compound BrCCOC1CCCCO1 GCUOLJOTJRUDIZ-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- WDFDLBVIJABSNV-UHFFFAOYSA-N 2-chloro-4-(3-chloropropyl)pyridine Chemical compound ClCCCC1=CC=NC(Cl)=C1 WDFDLBVIJABSNV-UHFFFAOYSA-N 0.000 description 3
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 3
- AMSDWLOANMAILF-UHFFFAOYSA-N 2-imidazol-1-ylethanol Chemical compound OCCN1C=CN=C1 AMSDWLOANMAILF-UHFFFAOYSA-N 0.000 description 3
- DWPYQDGDWBKJQL-UHFFFAOYSA-N 2-pyridin-4-ylethanol Chemical compound OCCC1=CC=NC=C1 DWPYQDGDWBKJQL-UHFFFAOYSA-N 0.000 description 3
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- NSNFLSUFJFOYIJ-UHFFFAOYSA-N 4-chloro-6-methoxy-7-phenylmethoxyquinazoline;hydrochloride Chemical compound Cl.COC1=CC2=C(Cl)N=CN=C2C=C1OCC1=CC=CC=C1 NSNFLSUFJFOYIJ-UHFFFAOYSA-N 0.000 description 3
- PVMNPAUTCMBOMO-UHFFFAOYSA-N 4-chloropyridine Chemical compound ClC1=CC=NC=C1 PVMNPAUTCMBOMO-UHFFFAOYSA-N 0.000 description 3
- AFZLCOLNTRPSIF-UHFFFAOYSA-N 5-amino-2-chloro-4-fluorophenol Chemical compound NC1=CC(O)=C(Cl)C=C1F AFZLCOLNTRPSIF-UHFFFAOYSA-N 0.000 description 3
- KCORZHJVTZIZFD-UHFFFAOYSA-N 7-fluoro-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C=2C1=CC(F)=CC=2 KCORZHJVTZIZFD-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- PXUIKGFZEWETFP-UHFFFAOYSA-N COC1=C(C=C2C(=C1)C(=NC(=N2)N(C3=CC=CC=C3)F)Cl)O Chemical compound COC1=C(C=C2C(=C1)C(=NC(=N2)N(C3=CC=CC=C3)F)Cl)O PXUIKGFZEWETFP-UHFFFAOYSA-N 0.000 description 3
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 108091008605 VEGF receptors Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 230000001772 anti-angiogenic effect Effects 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 201000011066 hemangioma Diseases 0.000 description 3
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 3
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 235000021243 milk fat Nutrition 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 3
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- RVQZKNOMKUSGCI-UHFFFAOYSA-N pyridine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC=C1 RVQZKNOMKUSGCI-UHFFFAOYSA-N 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 238000001665 trituration Methods 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- 239000000052 vinegar Substances 0.000 description 3
- 235000021419 vinegar Nutrition 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- SQRSIOZFPSFABI-UHFFFAOYSA-N (1-methylbenzimidazol-2-yl)methanol Chemical compound C1=CC=C2N(C)C(CO)=NC2=C1 SQRSIOZFPSFABI-UHFFFAOYSA-N 0.000 description 2
- LGAAPDVGNCACDI-UHFFFAOYSA-N (2-chloro-6-methoxypyridin-4-yl)methanol Chemical compound COC1=CC(CO)=CC(Cl)=N1 LGAAPDVGNCACDI-UHFFFAOYSA-N 0.000 description 2
- YXPVCSWOMRFRCS-UHFFFAOYSA-N (2-chloro-6-methylpyridin-4-yl)methanol Chemical compound CC1=CC(CO)=CC(Cl)=N1 YXPVCSWOMRFRCS-UHFFFAOYSA-N 0.000 description 2
- YENBVKZRNXXJSF-UHFFFAOYSA-N (2-methoxypyridin-4-yl)methanol Chemical compound COC1=CC(CO)=CC=N1 YENBVKZRNXXJSF-UHFFFAOYSA-N 0.000 description 2
- IHPUFQUSNFAXHH-UHFFFAOYSA-N (4-fluoro-5-hydroxy-2-methylphenyl) methyl carbonate Chemical compound COC(=O)OC1=CC(O)=C(F)C=C1C IHPUFQUSNFAXHH-UHFFFAOYSA-N 0.000 description 2
- GJXWNWKCYDISGQ-UHFFFAOYSA-N (5-amino-4-fluoro-2-methylphenyl) methyl carbonate Chemical compound COC(=O)OC1=CC(N)=C(F)C=C1C GJXWNWKCYDISGQ-UHFFFAOYSA-N 0.000 description 2
- NZXRRNLMXLRCAF-UHFFFAOYSA-N (7-hydroxy-6-methoxy-4-oxoquinazolin-3-yl)methyl 2,2-dimethylpropanoate Chemical compound N1=CN(COC(=O)C(C)(C)C)C(=O)C2=C1C=C(O)C(OC)=C2 NZXRRNLMXLRCAF-UHFFFAOYSA-N 0.000 description 2
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 2
- GEYGQGNEYQUCMB-UHFFFAOYSA-N 1-(2-hydroxyethyl)pyridin-4-one Chemical compound OCCN1C=CC(=O)C=C1 GEYGQGNEYQUCMB-UHFFFAOYSA-N 0.000 description 2
- LLPKQRMDOFYSGZ-UHFFFAOYSA-N 2,5-dimethyl-1h-imidazole Chemical compound CC1=CN=C(C)N1 LLPKQRMDOFYSGZ-UHFFFAOYSA-N 0.000 description 2
- PDTPACVTCXCMLH-UHFFFAOYSA-N 2-(2-chloroethoxy)pyridine;hydrochloride Chemical compound Cl.ClCCOC1=CC=CC=N1 PDTPACVTCXCMLH-UHFFFAOYSA-N 0.000 description 2
- UVRIANWWLYCHRE-UHFFFAOYSA-N 2-(2-chloroethylsulfanyl)-1-methylimidazole;hydrochloride Chemical compound Cl.CN1C=CN=C1SCCCl UVRIANWWLYCHRE-UHFFFAOYSA-N 0.000 description 2
- HJNHUFQGDJLQRS-UHFFFAOYSA-N 2-(3-bromopropoxy)oxane Chemical compound BrCCCOC1CCCCO1 HJNHUFQGDJLQRS-UHFFFAOYSA-N 0.000 description 2
- WRGVPFAJPMIYOX-UHFFFAOYSA-N 2-(chloromethyl)-1-methylbenzimidazole Chemical compound C1=CC=C2N(C)C(CCl)=NC2=C1 WRGVPFAJPMIYOX-UHFFFAOYSA-N 0.000 description 2
- JDIPKQBKSBWIKU-UHFFFAOYSA-N 2-(chloromethyl)-1-methylimidazole;hydrochloride Chemical compound Cl.CN1C=CN=C1CCl JDIPKQBKSBWIKU-UHFFFAOYSA-N 0.000 description 2
- BTHLFVFUIJKXHV-UHFFFAOYSA-N 2-[methyl(pyridazin-4-yl)amino]ethanol Chemical compound OCCN(C)C1=CC=NN=C1 BTHLFVFUIJKXHV-UHFFFAOYSA-N 0.000 description 2
- 125000006016 2-bromoethoxy group Chemical group 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 2
- IFBXNOIFACMNNE-UHFFFAOYSA-N 2-pyridin-3-yloxyethanol Chemical compound OCCOC1=CC=CN=C1 IFBXNOIFACMNNE-UHFFFAOYSA-N 0.000 description 2
- DBRWSSMTVPPQJP-UHFFFAOYSA-N 3-(2-chloroethoxy)pyridine;hydrochloride Chemical compound Cl.ClCCOC1=CC=CN=C1 DBRWSSMTVPPQJP-UHFFFAOYSA-N 0.000 description 2
- BOWIFWCBNWWZOG-UHFFFAOYSA-N 3-Thiophenemethanol Chemical compound OCC=1C=CSC=1 BOWIFWCBNWWZOG-UHFFFAOYSA-N 0.000 description 2
- HLWIOFLZKFTSHE-UHFFFAOYSA-N 3-pyridin-4-yloxypropan-1-ol Chemical compound OCCCOC1=CC=NC=C1 HLWIOFLZKFTSHE-UHFFFAOYSA-N 0.000 description 2
- BZTRSSTYEMLIQT-UHFFFAOYSA-N 3-pyridin-4-ylprop-1-en-1-ol Chemical compound OC=CCC1=CC=NC=C1 BZTRSSTYEMLIQT-UHFFFAOYSA-N 0.000 description 2
- APWATYSLGSIOAU-UHFFFAOYSA-N 4-(2-chloroethoxy)pyridine;hydrochloride Chemical compound Cl.ClCCOC1=CC=NC=C1 APWATYSLGSIOAU-UHFFFAOYSA-N 0.000 description 2
- RMAWPGJUJDOZOM-UHFFFAOYSA-N 4-(3-chloropropoxy)pyridine;hydrochloride Chemical compound Cl.ClCCCOC1=CC=NC=C1 RMAWPGJUJDOZOM-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- AQBBZYVPKBIILN-UHFFFAOYSA-N 4-(chloromethyl)-2-methyl-1,3-thiazole Chemical compound CC1=NC(CCl)=CS1 AQBBZYVPKBIILN-UHFFFAOYSA-N 0.000 description 2
- ZJSSDJCFSASGNQ-UHFFFAOYSA-N 4-(hydroxymethyl)pyridine-2-carbonitrile Chemical compound OCC1=CC=NC(C#N)=C1 ZJSSDJCFSASGNQ-UHFFFAOYSA-N 0.000 description 2
- SXLOLZRGTFLFMI-UHFFFAOYSA-N 4-chloro-6-methoxy-7-(pyridin-4-ylmethoxy)quinazoline Chemical compound COC1=CC2=C(Cl)N=CN=C2C=C1OCC1=CC=NC=C1 SXLOLZRGTFLFMI-UHFFFAOYSA-N 0.000 description 2
- WAXPNWDFFTXGCR-UHFFFAOYSA-N 4-chloro-7-nitroquinazoline;hydrochloride Chemical compound Cl.ClC1=NC=NC2=CC([N+](=O)[O-])=CC=C21 WAXPNWDFFTXGCR-UHFFFAOYSA-N 0.000 description 2
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 2
- LVILGAOSPDLNRM-UHFFFAOYSA-N 4-methylpyrimidine Chemical compound CC1=CC=NC=N1 LVILGAOSPDLNRM-UHFFFAOYSA-N 0.000 description 2
- WPDJCYRVGAKHIX-UHFFFAOYSA-N 5-[[6-methoxy-7-(pyrimidin-4-ylmethoxy)quinazolin-4-yl]amino]-2-methylphenol Chemical group N1=CN=C2C=C(OCC=3N=CN=CC=3)C(OC)=CC2=C1NC1=CC=C(C)C(O)=C1 WPDJCYRVGAKHIX-UHFFFAOYSA-N 0.000 description 2
- YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 description 2
- GWSZZANIALCAJM-UHFFFAOYSA-N 6-methoxy-4-phenoxyquinazolin-7-ol Chemical compound N1=CN=C2C=C(O)C(OC)=CC2=C1OC1=CC=CC=C1 GWSZZANIALCAJM-UHFFFAOYSA-N 0.000 description 2
- CTMPEESMAXZQCR-UHFFFAOYSA-N 7-(pyridin-4-ylmethoxy)-1h-quinazolin-4-one Chemical compound C=1C=C2C(=O)NC=NC2=CC=1OCC1=CC=NC=C1 CTMPEESMAXZQCR-UHFFFAOYSA-N 0.000 description 2
- RVHGIEORPPARCS-UHFFFAOYSA-N 7-pyridin-4-ylsulfanyl-1h-quinazolin-4-one Chemical compound C=1C=C2C(=O)NC=NC2=CC=1SC1=CC=NC=C1 RVHGIEORPPARCS-UHFFFAOYSA-N 0.000 description 2
- 108010079709 Angiostatins Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- FAYSHERMYLEANM-UHFFFAOYSA-N CC1(SC=CN1)C(=O)O Chemical compound CC1(SC=CN1)C(=O)O FAYSHERMYLEANM-UHFFFAOYSA-N 0.000 description 2
- LYZYSZVWTUTCKT-UHFFFAOYSA-N COC1=C(C=C2C(=C1)C=NC(=N2)N(C3=CC=CC=C3)F)O Chemical compound COC1=C(C=C2C(=C1)C=NC(=N2)N(C3=CC=CC=C3)F)O LYZYSZVWTUTCKT-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 2
- 240000001812 Hyssopus officinalis Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 2
- 241001553014 Myrsine salicina Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical class C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 2
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
- KWBZFNCQXIFTFY-UHFFFAOYSA-N [5-[[7-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]-6-methoxyquinazolin-4-yl]amino]-2-methylphenyl] acetate Chemical compound N1=CN=C2C=C(OCC3=C(ON=C3C)C)C(OC)=CC2=C1NC1=CC=C(C)C(OC(C)=O)=C1 KWBZFNCQXIFTFY-UHFFFAOYSA-N 0.000 description 2
- VLBNTQXQUXPEDA-UHFFFAOYSA-N [6-methoxy-7-[2-(methylamino)ethoxy]-4-oxoquinazolin-3-yl]methyl 2,2-dimethylpropanoate Chemical compound N1=CN(COC(=O)C(C)(C)C)C(=O)C2=C1C=C(OCCNC)C(OC)=C2 VLBNTQXQUXPEDA-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Chemical class CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- RMRFFCXPLWYOOY-UHFFFAOYSA-N allyl radical Chemical group [CH2]C=C RMRFFCXPLWYOOY-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000003849 aromatic solvent Substances 0.000 description 2
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- KQTXIZHBFFWWFW-UHFFFAOYSA-L disilver;carbonate Chemical compound [Ag]OC(=O)O[Ag] KQTXIZHBFFWWFW-UHFFFAOYSA-L 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229950007919 egtazic acid Drugs 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229950002007 estradiol benzoate Drugs 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229960005337 lysine hydrochloride Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 2
- 229950008959 marimastat Drugs 0.000 description 2
- BDWMGYZSQKGUFA-UHFFFAOYSA-N methyl 2-chloro-6-methylpyridine-4-carboxylate Chemical compound COC(=O)C1=CC(C)=NC(Cl)=C1 BDWMGYZSQKGUFA-UHFFFAOYSA-N 0.000 description 2
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 2
- AVWUHZZARFAVLF-UHFFFAOYSA-N n-(2-hydroxyethyl)-n,2,2-trimethylpropanamide Chemical compound OCCN(C)C(=O)C(C)(C)C AVWUHZZARFAVLF-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- ZIDNDHOWBISBIO-UHFFFAOYSA-N quinazoline;hydrate;hydrochloride Chemical compound O.Cl.N1=CN=CC2=CC=CC=C21 ZIDNDHOWBISBIO-UHFFFAOYSA-N 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- AGMNGTMFRYIJLD-UHFFFAOYSA-N tert-butyl n-[2-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxyethyl]-n-methylcarbamate Chemical compound N1=CN=C2C=C(OCCN(C)C(=O)OC(C)(C)C)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F AGMNGTMFRYIJLD-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- ZPHGMBGIFODUMF-UHFFFAOYSA-N thiophen-2-ylmethanol Chemical compound OCC1=CC=CS1 ZPHGMBGIFODUMF-UHFFFAOYSA-N 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- UMFCIIBZHQXRCJ-NSCUHMNNSA-N trans-anol Chemical compound C\C=C\C1=CC=C(O)C=C1 UMFCIIBZHQXRCJ-NSCUHMNNSA-N 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- CDQDMLWGTVLQEE-UHFFFAOYSA-N (1-methylimidazol-2-yl)methanol Chemical compound CN1C=CN=C1CO CDQDMLWGTVLQEE-UHFFFAOYSA-N 0.000 description 1
- YDGJTFCKLFLWFM-UHFFFAOYSA-N (2,6-dichloropyridin-4-yl)methanol Chemical compound OCC1=CC(Cl)=NC(Cl)=C1 YDGJTFCKLFLWFM-UHFFFAOYSA-N 0.000 description 1
- KRCIFTBSQKDYMH-UHFFFAOYSA-N (2-methyl-1,3-thiazol-4-yl)methanol Chemical compound CC1=NC(CO)=CS1 KRCIFTBSQKDYMH-UHFFFAOYSA-N 0.000 description 1
- ZNDOXROITOAJQJ-UHFFFAOYSA-N (2-methyl-5-nitrophenyl) acetate Chemical compound CC(=O)OC1=CC([N+]([O-])=O)=CC=C1C ZNDOXROITOAJQJ-UHFFFAOYSA-N 0.000 description 1
- WCHFSXVRRCEWJL-UHFFFAOYSA-N (2-methylpyridin-4-yl)methanol Chemical compound CC1=CC(CO)=CC=N1 WCHFSXVRRCEWJL-UHFFFAOYSA-N 0.000 description 1
- ZFYIQPIHXRFFCZ-QMMMGPOBSA-N (2s)-2-(cyclohexylamino)butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC1CCCCC1 ZFYIQPIHXRFFCZ-QMMMGPOBSA-N 0.000 description 1
- KIQNTUVEIYAMDA-UHFFFAOYSA-N (4-fluoro-2-methylphenyl) methyl carbonate Chemical compound COC(=O)OC1=CC=C(F)C=C1C KIQNTUVEIYAMDA-UHFFFAOYSA-N 0.000 description 1
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 1
- UXSGTKIRBLSJEX-UHFFFAOYSA-N (6-methoxy-4-oxoquinazolin-3-yl)methyl 2,2-dimethylpropanoate Chemical compound N1=CN(COC(=O)C(C)(C)C)C(=O)C2=CC(OC)=CC=C21 UXSGTKIRBLSJEX-UHFFFAOYSA-N 0.000 description 1
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- CRPTXKKKIGGDBX-UHFFFAOYSA-N (z)-but-2-ene Chemical group [CH2]C=CC CRPTXKKKIGGDBX-UHFFFAOYSA-N 0.000 description 1
- GSMCDXGKZOUAET-UHFFFAOYSA-N (z)-pent-2-ene Chemical group C[CH]C=CC GSMCDXGKZOUAET-UHFFFAOYSA-N 0.000 description 1
- SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 1
- 125000001401 1,2,4-triazol-4-yl group Chemical group N=1N=C([H])N([*])C=1[H] 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- PJWNJWGPRUXBMC-UHFFFAOYSA-N 1-(2-chloroethyl)pyridin-2-one Chemical compound ClCCN1C=CC=CC1=O PJWNJWGPRUXBMC-UHFFFAOYSA-N 0.000 description 1
- UQKTWONKBNNXHL-UHFFFAOYSA-N 1-(3-chloropropyl)pyridin-2-one Chemical compound ClCCCN1C=CC=CC1=O UQKTWONKBNNXHL-UHFFFAOYSA-N 0.000 description 1
- QLAGPCJUAFNZGR-UHFFFAOYSA-N 1-(3-hydroxypropyl)pyridin-2-one Chemical compound OCCCN1C=CC=CC1=O QLAGPCJUAFNZGR-UHFFFAOYSA-N 0.000 description 1
- PMARXWBRXYBABD-UHFFFAOYSA-N 1-(3-hydroxypropyl)pyridin-4-one Chemical compound OCCCN1C=CC(=O)C=C1 PMARXWBRXYBABD-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- KTVFWSOPMRZAQX-UHFFFAOYSA-N 1-[2-(oxan-2-yloxy)ethyl]pyridin-4-one Chemical compound C1=CC(=O)C=CN1CCOC1OCCCC1 KTVFWSOPMRZAQX-UHFFFAOYSA-N 0.000 description 1
- HIXISIAJTKTHNJ-UHFFFAOYSA-N 1-methyl-2-[3-(oxan-2-yloxy)propylsulfanyl]imidazole Chemical compound CN1C=CN=C1SCCCOC1OCCCC1 HIXISIAJTKTHNJ-UHFFFAOYSA-N 0.000 description 1
- FGYADSCZTQOAFK-UHFFFAOYSA-N 1-methylbenzimidazole Chemical compound C1=CC=C2N(C)C=NC2=C1 FGYADSCZTQOAFK-UHFFFAOYSA-N 0.000 description 1
- RBLWIBNMCJMLBU-UHFFFAOYSA-N 1-propylpyridin-2-one Chemical compound CCCN1C=CC=CC1=O RBLWIBNMCJMLBU-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical compound C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 1
- FHTDDANQIMVWKZ-UHFFFAOYSA-N 1h-pyridine-4-thione Chemical compound SC1=CC=NC=C1 FHTDDANQIMVWKZ-UHFFFAOYSA-N 0.000 description 1
- UIQGEWJEWJMQSL-UHFFFAOYSA-N 2,2,4,4-tetramethylpentan-3-one Chemical group CC(C)(C)C(=O)C(C)(C)C UIQGEWJEWJMQSL-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- KLPANOPBGAZTMV-UHFFFAOYSA-N 2,6-dimethoxyquinazoline Chemical compound COC1=NC2=CC=C(C=C2C=N1)OC KLPANOPBGAZTMV-UHFFFAOYSA-N 0.000 description 1
- ZIUFRNJJYYWPSD-UHFFFAOYSA-N 2,6-dimethoxyquinazoline hydrochloride Chemical compound Cl.COC1=NC2=CC=C(C=C2C=N1)OC ZIUFRNJJYYWPSD-UHFFFAOYSA-N 0.000 description 1
- XMHVEJIITNFCBG-UHFFFAOYSA-N 2-(1-methylimidazol-2-yl)sulfanylethanol Chemical compound CN1C=CN=C1SCCO XMHVEJIITNFCBG-UHFFFAOYSA-N 0.000 description 1
- KYKCDYXGOLDLPO-UHFFFAOYSA-N 2-(2,5-dimethylimidazol-1-yl)ethanol Chemical compound CC1=CN=C(C)N1CCO KYKCDYXGOLDLPO-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- MBDKFHRMTCYWQP-UHFFFAOYSA-N 2-(3,5-dimethyl-1,2,4-triazol-4-yl)ethanol Chemical compound CC1=NN=C(C)N1CCO MBDKFHRMTCYWQP-UHFFFAOYSA-N 0.000 description 1
- GKPLVLMZRSSUIS-UHFFFAOYSA-N 2-(3-chloropropylsulfanyl)-1-methylimidazole;hydrochloride Chemical compound Cl.CN1C=CN=C1SCCCCl GKPLVLMZRSSUIS-UHFFFAOYSA-N 0.000 description 1
- QJHOHDKABVJMEC-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)ethanol Chemical compound CC1=CC=CC(CCO)=N1 QJHOHDKABVJMEC-UHFFFAOYSA-N 0.000 description 1
- NJWIMFZLESWFIM-UHFFFAOYSA-N 2-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC=N1 NJWIMFZLESWFIM-UHFFFAOYSA-N 0.000 description 1
- JPMRGPPMXHGKRO-UHFFFAOYSA-N 2-(chloromethyl)pyridine hydrochloride Chemical compound Cl.ClCC1=CC=CC=N1 JPMRGPPMXHGKRO-UHFFFAOYSA-N 0.000 description 1
- MGSLNQCOIOCSBQ-UHFFFAOYSA-N 2-(pyridin-4-ylamino)ethanol Chemical compound OCCNC1=CC=NC=C1 MGSLNQCOIOCSBQ-UHFFFAOYSA-N 0.000 description 1
- XRAAHSVINPEJGU-UHFFFAOYSA-N 2-[3-(oxan-2-yloxy)propoxy]pyridine Chemical compound C=1C=CC=NC=1OCCCOC1CCCCO1 XRAAHSVINPEJGU-UHFFFAOYSA-N 0.000 description 1
- LGPVTNAJFDUWLF-UHFFFAOYSA-N 2-amino-4-fluorobenzoic acid Chemical compound NC1=CC(F)=CC=C1C(O)=O LGPVTNAJFDUWLF-UHFFFAOYSA-N 0.000 description 1
- DNPHXICYCDCOAR-UHFFFAOYSA-N 2-amino-5-methoxy-4-phenylmethoxybenzamide Chemical compound COC1=CC(C(N)=O)=C(N)C=C1OCC1=CC=CC=C1 DNPHXICYCDCOAR-UHFFFAOYSA-N 0.000 description 1
- MWSJMNJBKAPIOX-UHFFFAOYSA-N 2-bromo-4-(bromomethyl)pyridine Chemical compound BrCC1=CC=NC(Br)=C1 MWSJMNJBKAPIOX-UHFFFAOYSA-N 0.000 description 1
- LSZMVESSGLHDJE-UHFFFAOYSA-N 2-bromo-4-methylpyridine Chemical compound CC1=CC=NC(Br)=C1 LSZMVESSGLHDJE-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- JTVTXIFSVIMPGN-UHFFFAOYSA-N 2-chloro-4-(chloromethyl)-6-methoxypyridine;hydrochloride Chemical compound Cl.COC1=CC(CCl)=CC(Cl)=N1 JTVTXIFSVIMPGN-UHFFFAOYSA-N 0.000 description 1
- QELZCGMVHLQNSO-UHFFFAOYSA-N 2-chloro-4-(chloromethyl)pyridine Chemical compound ClCC1=CC=NC(Cl)=C1 QELZCGMVHLQNSO-UHFFFAOYSA-N 0.000 description 1
- JYLHSVRWUGHRKL-UHFFFAOYSA-N 2-chloro-4-fluoro-5-[[6-methoxy-7-(2-pyridin-4-ylethoxy)quinazolin-2-yl]amino]phenol Chemical compound N1=C2C=C(OCCC=3C=CN=CC=3)C(OC)=CC2=CN=C1NC1=CC(O)=C(Cl)C=C1F JYLHSVRWUGHRKL-UHFFFAOYSA-N 0.000 description 1
- JCLVVOFEMLEEBJ-UHFFFAOYSA-N 2-chloro-4-fluoro-5-[[6-methoxy-7-(thiophen-3-ylmethoxy)quinazolin-4-yl]amino]phenol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC3=CSC=C3)C(OC)=CC2=C1NC1=CC(O)=C(Cl)C=C1F JCLVVOFEMLEEBJ-UHFFFAOYSA-N 0.000 description 1
- MLSXUINFTKYOBU-UHFFFAOYSA-N 2-chloro-4-fluoro-5-[[6-methoxy-7-[(1-methylimidazol-2-yl)methoxy]quinazolin-4-yl]amino]phenol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC=3N(C=CN=3)C)C(OC)=CC2=C1NC1=CC(O)=C(Cl)C=C1F MLSXUINFTKYOBU-UHFFFAOYSA-N 0.000 description 1
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- DPNDWFVORIGXQO-UHFFFAOYSA-N 2-methoxypyridine-4-carboxylic acid Chemical compound COC1=CC(C(O)=O)=CC=N1 DPNDWFVORIGXQO-UHFFFAOYSA-N 0.000 description 1
- CTWUBHYVOQXKLS-UHFFFAOYSA-N 2-methyl-5-[(7-pyridin-4-ylsulfanylquinazolin-4-yl)amino]phenol;hydrochloride Chemical compound Cl.C1=C(O)C(C)=CC=C1NC1=NC=NC2=CC(SC=3C=CN=CC=3)=CC=C12 CTWUBHYVOQXKLS-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- UMFDLIXUUJMPSI-UHFFFAOYSA-N 2-methyl-5-nitrophenol Chemical compound CC1=CC=C([N+]([O-])=O)C=C1O UMFDLIXUUJMPSI-UHFFFAOYSA-N 0.000 description 1
- PMDHIMMPXRSDML-UHFFFAOYSA-N 2-methylpyridine-4-carboxylic acid Chemical compound CC1=CC(C(O)=O)=CC=N1 PMDHIMMPXRSDML-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- RKBOVIXFWKGJLG-UHFFFAOYSA-N 2-pyridin-2-yloxyethanol Chemical compound OCCOC1=CC=CC=N1 RKBOVIXFWKGJLG-UHFFFAOYSA-N 0.000 description 1
- YPWSASPSYAWQRK-UHFFFAOYSA-N 2-pyridin-3-ylethanol Chemical compound OCCC1=CC=CN=C1 YPWSASPSYAWQRK-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- FQHKVJXHFTZBOU-UHFFFAOYSA-N 3,4-dihydro-2h-pyrrole;hydrochloride Chemical compound Cl.C1CC=NC1 FQHKVJXHFTZBOU-UHFFFAOYSA-N 0.000 description 1
- IFIXOVUEWNCJED-UHFFFAOYSA-N 3-(1,2,4-triazol-1-yl)propan-1-ol Chemical compound OCCCN1C=NC=N1 IFIXOVUEWNCJED-UHFFFAOYSA-N 0.000 description 1
- JNDSACOKGJNFMH-UHFFFAOYSA-N 3-(1-methylimidazol-2-yl)sulfanylpropan-1-ol Chemical compound CN1C=CN=C1SCCCO JNDSACOKGJNFMH-UHFFFAOYSA-N 0.000 description 1
- YAWYZRXSWDINCM-UHFFFAOYSA-N 3-(2-methylimidazol-1-yl)propan-1-ol Chemical compound CC1=NC=CN1CCCO YAWYZRXSWDINCM-UHFFFAOYSA-N 0.000 description 1
- FNHPUOJKUXFUKN-UHFFFAOYSA-N 3-(bromomethyl)pyridine;hydron;bromide Chemical compound Br.BrCC1=CC=CN=C1 FNHPUOJKUXFUKN-UHFFFAOYSA-N 0.000 description 1
- UZGLOGCJCWBBIV-UHFFFAOYSA-N 3-(chloromethyl)pyridin-1-ium;chloride Chemical compound Cl.ClCC1=CC=CN=C1 UZGLOGCJCWBBIV-UHFFFAOYSA-N 0.000 description 1
- KKWWFYAKOFXBEY-UHFFFAOYSA-N 3-(chloromethyl)thiophene Chemical compound ClCC=1C=CSC=1 KKWWFYAKOFXBEY-UHFFFAOYSA-N 0.000 description 1
- RTWUCGSQKRVHFL-UHFFFAOYSA-N 3-(fluoroamino)phenol Chemical compound OC1=CC=CC(NF)=C1 RTWUCGSQKRVHFL-UHFFFAOYSA-N 0.000 description 1
- UXNSNQMIQBFIIG-UHFFFAOYSA-N 3-[[7-(2-imidazol-1-ylethoxy)-6-methoxyquinazolin-4-yl]amino]phenol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCCN3C=NC=C3)C(OC)=CC2=C1NC1=CC=CC(O)=C1 UXNSNQMIQBFIIG-UHFFFAOYSA-N 0.000 description 1
- CWLKGDAVCFYWJK-UHFFFAOYSA-N 3-aminophenol Chemical compound NC1=CC=CC(O)=C1 CWLKGDAVCFYWJK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- RYZVYLGJZFNBND-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-ol Chemical compound OCCCN1C=CN=C1 RYZVYLGJZFNBND-UHFFFAOYSA-N 0.000 description 1
- FUCYABRIJPUVAT-UHFFFAOYSA-N 3-phenylmethoxypropan-1-ol Chemical compound OCCCOCC1=CC=CC=C1 FUCYABRIJPUVAT-UHFFFAOYSA-N 0.000 description 1
- PZVZGDBCMQBRMA-UHFFFAOYSA-N 3-pyridin-4-ylpropan-1-ol Chemical compound OCCCC1=CC=NC=C1 PZVZGDBCMQBRMA-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- RGXUWZCNLSMYQW-UHFFFAOYSA-N 4-(2-chloroethylsulfanyl)pyridine;hydrochloride Chemical compound Cl.ClCCSC1=CC=NC=C1 RGXUWZCNLSMYQW-UHFFFAOYSA-N 0.000 description 1
- XTJQMHZWPVZEHX-UHFFFAOYSA-N 4-(4-chloro-2-fluorophenoxy)-6-methoxy-7-(pyridin-4-ylmethoxy)quinazoline Chemical compound N1=CN=C2C=C(OCC=3C=CN=CC=3)C(OC)=CC2=C1OC1=CC=C(Cl)C=C1F XTJQMHZWPVZEHX-UHFFFAOYSA-N 0.000 description 1
- GNXBVAVHLYJXPE-UHFFFAOYSA-N 4-(4-chloro-2-fluorophenoxy)-6-methoxy-7-phenylmethoxyquinazoline Chemical compound N1=CN=C2C=C(OCC=3C=CC=CC=3)C(OC)=CC2=C1OC1=CC=C(Cl)C=C1F GNXBVAVHLYJXPE-UHFFFAOYSA-N 0.000 description 1
- GDNCYIJCRVHXRX-UHFFFAOYSA-N 4-(4-chloro-2-fluorophenoxy)-6-methoxyquinazolin-7-ol Chemical compound N1=CN=C2C=C(O)C(OC)=CC2=C1OC1=CC=C(Cl)C=C1F GDNCYIJCRVHXRX-UHFFFAOYSA-N 0.000 description 1
- JJIFTOPVKWDHJI-UHFFFAOYSA-N 4-(bromomethyl)-1,2-difluorobenzene Chemical compound FC1=CC=C(CBr)C=C1F JJIFTOPVKWDHJI-UHFFFAOYSA-N 0.000 description 1
- VAJUUDUWDNCECT-UHFFFAOYSA-N 4-(bromomethyl)pyridine;hydron;bromide Chemical compound Br.BrCC1=CC=NC=C1 VAJUUDUWDNCECT-UHFFFAOYSA-N 0.000 description 1
- SDOUAZHZDPGZHP-UHFFFAOYSA-N 4-(chloromethyl)-2-methoxypyridine Chemical compound COC1=CC(CCl)=CC=N1 SDOUAZHZDPGZHP-UHFFFAOYSA-N 0.000 description 1
- YGKDISJLDVGNOR-UHFFFAOYSA-N 4-(chloromethyl)-2-methyl-1,3-thiazole;hydrochloride Chemical compound Cl.CC1=NC(CCl)=CS1 YGKDISJLDVGNOR-UHFFFAOYSA-N 0.000 description 1
- MUEOGQBVZGRFJN-UHFFFAOYSA-N 4-(chloromethyl)-2-methylpyridine;hydrochloride Chemical compound Cl.CC1=CC(CCl)=CC=N1 MUEOGQBVZGRFJN-UHFFFAOYSA-N 0.000 description 1
- ZDHKVKPZQKYREU-UHFFFAOYSA-N 4-(chloromethyl)pyridine;hydron;chloride Chemical compound Cl.ClCC1=CC=NC=C1 ZDHKVKPZQKYREU-UHFFFAOYSA-N 0.000 description 1
- NWPTUIGYTCHXAG-UHFFFAOYSA-N 4-[[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxymethyl]pyridine-2-carbonitrile Chemical compound N1=CN=C2C=C(OCC=3C=C(N=CC=3)C#N)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F NWPTUIGYTCHXAG-UHFFFAOYSA-N 0.000 description 1
- GZRMNMGWNKSANY-UHFFFAOYSA-N 4-bromo-2-fluoroaniline Chemical compound NC1=CC=C(Br)C=C1F GZRMNMGWNKSANY-UHFFFAOYSA-N 0.000 description 1
- XAXKZIUQIROVNV-UHFFFAOYSA-N 4-bromo-3,6-dichloropyridazine Chemical compound ClC1=CC(Br)=C(Cl)N=N1 XAXKZIUQIROVNV-UHFFFAOYSA-N 0.000 description 1
- SXCXPXVEOPFPOH-UHFFFAOYSA-N 4-chloro-2,6-dimethylpyridine Chemical compound CC1=CC(Cl)=CC(C)=N1 SXCXPXVEOPFPOH-UHFFFAOYSA-N 0.000 description 1
- ZKMUKBBWORLNLA-UHFFFAOYSA-N 4-chloro-2-fluorophenol Chemical compound OC1=CC=C(Cl)C=C1F ZKMUKBBWORLNLA-UHFFFAOYSA-N 0.000 description 1
- RLPAUIIPFPSCEE-UHFFFAOYSA-N 4-chloro-6-methoxy-7-[2-(1,2,4-triazol-1-yl)ethoxy]quinazoline Chemical compound COC1=CC2=C(Cl)N=CN=C2C=C1OCCN1C=NC=N1 RLPAUIIPFPSCEE-UHFFFAOYSA-N 0.000 description 1
- XXRANIZVRMJFTH-UHFFFAOYSA-N 4-chloro-6-methyl-1h-pyrimidin-2-one Chemical compound CC1=CC(Cl)=NC(O)=N1 XXRANIZVRMJFTH-UHFFFAOYSA-N 0.000 description 1
- FILIAKNTYOYOOQ-UHFFFAOYSA-N 4-chloro-7-(2-imidazol-1-ylethoxy)-6-methoxyquinazoline Chemical compound COC1=CC2=C(Cl)N=CN=C2C=C1OCCN1C=CN=C1 FILIAKNTYOYOOQ-UHFFFAOYSA-N 0.000 description 1
- SIEVPWQFNYWWHQ-UHFFFAOYSA-N 4-chloro-7-phenylmethoxyquinazoline;hydrochloride Chemical compound Cl.C=1C=C2C(Cl)=NC=NC2=CC=1OCC1=CC=CC=C1 SIEVPWQFNYWWHQ-UHFFFAOYSA-N 0.000 description 1
- ADDWHEAMADZSQK-UHFFFAOYSA-N 4-fluoro-2-methyl-5-[[7-[2-(1,2,4-triazol-1-yl)ethoxy]quinazolin-4-yl]amino]phenol;hydrochloride Chemical compound Cl.C1=C(O)C(C)=CC(F)=C1NC1=NC=NC2=CC(OCCN3N=CN=C3)=CC=C12 ADDWHEAMADZSQK-UHFFFAOYSA-N 0.000 description 1
- RSHVJZUBABFJRL-UHFFFAOYSA-N 4-fluoro-2-methyl-5-nitrophenol Chemical compound CC1=CC(F)=C([N+]([O-])=O)C=C1O RSHVJZUBABFJRL-UHFFFAOYSA-N 0.000 description 1
- IXYRPLSVOXJHIY-UHFFFAOYSA-N 4-fluoro-5-[[6-methoxy-7-(pyridin-4-ylmethoxy)quinazolin-4-yl]amino]-2-methylphenol Chemical compound N1=CN=C2C=C(OCC=3C=CN=CC=3)C(OC)=CC2=C1NC1=CC(O)=C(C)C=C1F IXYRPLSVOXJHIY-UHFFFAOYSA-N 0.000 description 1
- SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- CRQBTOFJOCQZDM-UHFFFAOYSA-N 5-[[6-methoxy-7-(3-pyridin-4-ylpropoxy)quinazolin-4-yl]amino]-2-methylphenol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCCCC=3C=CN=CC=3)C(OC)=CC2=C1NC1=CC=C(C)C(O)=C1 CRQBTOFJOCQZDM-UHFFFAOYSA-N 0.000 description 1
- HRJXNLVYDUPXRU-UHFFFAOYSA-N 5-[[6-methoxy-7-(pyridin-3-ylmethoxy)quinazolin-4-yl]amino]-2-methylphenol Chemical compound N1=CN=C2C=C(OCC=3C=NC=CC=3)C(OC)=CC2=C1NC1=CC=C(C)C(O)=C1 HRJXNLVYDUPXRU-UHFFFAOYSA-N 0.000 description 1
- DNTDWHIFRIQQDI-UHFFFAOYSA-N 5-[[6-methoxy-7-(thiophen-3-ylmethoxy)quinazolin-4-yl]amino]-2-methylphenol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC3=CSC=C3)C(OC)=CC2=C1NC1=CC=C(C)C(O)=C1 DNTDWHIFRIQQDI-UHFFFAOYSA-N 0.000 description 1
- IDOSYLPYJNVYCX-UHFFFAOYSA-N 5-[[6-methoxy-7-[(1-methylbenzimidazol-2-yl)methoxy]quinazolin-4-yl]amino]-2-methylphenol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC=3N(C4=CC=CC=C4N=3)C)C(OC)=CC2=C1NC1=CC=C(C)C(O)=C1 IDOSYLPYJNVYCX-UHFFFAOYSA-N 0.000 description 1
- JEMGPDIOCNEKOC-UHFFFAOYSA-N 5-[[6-methoxy-7-[(2-methyl-1,3-thiazol-4-yl)methoxy]quinazolin-4-yl]amino]-2-methylphenol;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC=3N=C(C)SC=3)C(OC)=CC2=C1NC1=CC=C(C)C(O)=C1 JEMGPDIOCNEKOC-UHFFFAOYSA-N 0.000 description 1
- DBFYESDCPWWCHN-UHFFFAOYSA-N 5-amino-2-methylphenol Chemical compound CC1=CC=C(N)C=C1O DBFYESDCPWWCHN-UHFFFAOYSA-N 0.000 description 1
- NOFVNLZQAOGUIT-UHFFFAOYSA-N 6-methoxy-1h-quinazolin-4-one Chemical compound N1=CNC(=O)C2=CC(OC)=CC=C21 NOFVNLZQAOGUIT-UHFFFAOYSA-N 0.000 description 1
- OFKSYKUHUSRWQK-UHFFFAOYSA-N 6-methoxy-4-phenoxy-7-(pyridin-4-ylmethoxy)quinazoline Chemical compound N1=CN=C2C=C(OCC=3C=CN=CC=3)C(OC)=CC2=C1OC1=CC=CC=C1 OFKSYKUHUSRWQK-UHFFFAOYSA-N 0.000 description 1
- IYZQDPSQJLLWMS-UHFFFAOYSA-N 6-methoxy-4-phenoxy-7-phenylmethoxyquinazoline Chemical compound N1=CN=C2C=C(OCC=3C=CC=CC=3)C(OC)=CC2=C1OC1=CC=CC=C1 IYZQDPSQJLLWMS-UHFFFAOYSA-N 0.000 description 1
- WWCCVJZXAPJWSE-UHFFFAOYSA-N 6-methoxy-7-(pyridin-4-ylmethoxy)-1h-quinazolin-4-one Chemical compound COC1=CC(C(NC=N2)=O)=C2C=C1OCC1=CC=NC=C1 WWCCVJZXAPJWSE-UHFFFAOYSA-N 0.000 description 1
- ZCUFFSHMOAEEIL-UHFFFAOYSA-N 6-methoxy-7-phenylmethoxy-1h-quinazolin-4-one Chemical compound COC1=CC2=C(O)N=CN=C2C=C1OCC1=CC=CC=C1 ZCUFFSHMOAEEIL-UHFFFAOYSA-N 0.000 description 1
- VFSJPKSXNJQIFG-UHFFFAOYSA-N 6-methoxyquinazoline;hydrochloride Chemical compound Cl.N1=CN=CC2=CC(OC)=CC=C21 VFSJPKSXNJQIFG-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- PYYBFQKYBPFHQY-UHFFFAOYSA-N 7-[(2-bromopyridin-4-yl)methoxy]-n-(4-chloro-2-fluorophenyl)-6-methoxyquinazolin-4-amine Chemical compound N1=CN=C2C=C(OCC=3C=C(Br)N=CC=3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F PYYBFQKYBPFHQY-UHFFFAOYSA-N 0.000 description 1
- SWURWHWRUYLUQI-UHFFFAOYSA-N 7-[(2-chloro-6-oxo-1h-pyridin-4-yl)methoxy]-6-methoxy-1h-quinazolin-4-one Chemical compound COC1=CC(C(NC=N2)=O)=C2C=C1OCC=1C=C(Cl)NC(=O)C=1 SWURWHWRUYLUQI-UHFFFAOYSA-N 0.000 description 1
- XNGSGKJEWONQGN-UHFFFAOYSA-N 7-[(2-chloropyridin-4-yl)methoxy]-6-methoxy-1h-quinazolin-4-one Chemical compound COC1=CC(C(NC=N2)=O)=C2C=C1OCC1=CC=NC(Cl)=C1 XNGSGKJEWONQGN-UHFFFAOYSA-N 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 102000012936 Angiostatins Human genes 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 206010051113 Arterial restenosis Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FTGPXKLXDZIXJA-UHFFFAOYSA-N C(CSC1=NC=CC=C1)OC1OCCCC1 Chemical compound C(CSC1=NC=CC=C1)OC1OCCCC1 FTGPXKLXDZIXJA-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- CVJRTBGQGOQDTM-UHFFFAOYSA-N Cl.Oc1ccc2cncnc2c1 Chemical compound Cl.Oc1ccc2cncnc2c1 CVJRTBGQGOQDTM-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010092160 Dactinomycin Chemical class 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 101150048336 Flt1 gene Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 102100039875 Histone H3-7 Human genes 0.000 description 1
- 102100038736 Histone H3.3C Human genes 0.000 description 1
- 101001035307 Homo sapiens Histone H3-7 Proteins 0.000 description 1
- 101001031505 Homo sapiens Histone H3.3C Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- UKLPACCDWHFJCT-UHFFFAOYSA-N [2-(dimethylamino)pyridin-4-yl]methanol Chemical compound CN(C)C1=CC(CO)=CC=N1 UKLPACCDWHFJCT-UHFFFAOYSA-N 0.000 description 1
- QPXUGACTXZYBHT-UHFFFAOYSA-N [2-(methylamino)pyridin-4-yl]methanol Chemical compound CNC1=CC(CO)=CC=N1 QPXUGACTXZYBHT-UHFFFAOYSA-N 0.000 description 1
- CNBUUPORXPQKJU-UHFFFAOYSA-N [2-chloro-4-fluoro-5-[[6-methoxy-7-(3-pyridin-4-ylpropoxy)quinazolin-4-yl]amino]phenyl] methyl carbonate Chemical compound C1=C(Cl)C(OC(=O)OC)=CC(NC=2C3=CC(OC)=C(OCCCC=4C=CN=CC=4)C=C3N=CN=2)=C1F CNBUUPORXPQKJU-UHFFFAOYSA-N 0.000 description 1
- IXLKOFOPLMBWSI-UHFFFAOYSA-N [4-fluoro-5-[(6-methoxy-7-phenylmethoxyquinazolin-4-yl)amino]-2-methylphenyl] methyl carbonate;hydrochloride Chemical compound Cl.C1=C(C)C(OC(=O)OC)=CC(NC=2C3=CC(OC)=C(OCC=4C=CC=CC=4)C=C3N=CN=2)=C1F IXLKOFOPLMBWSI-UHFFFAOYSA-N 0.000 description 1
- IAPOSRGLUDKTMW-UHFFFAOYSA-N [5-[[6-methoxy-7-(pyridin-2-ylmethoxy)quinazolin-4-yl]amino]-2-methylphenyl] acetate Chemical compound N1=CN=C2C=C(OCC=3N=CC=CC=3)C(OC)=CC2=C1NC1=CC=C(C)C(OC(C)=O)=C1 IAPOSRGLUDKTMW-UHFFFAOYSA-N 0.000 description 1
- BQZQJUAMTWEOHY-UHFFFAOYSA-N [5-[[6-methoxy-7-(pyridin-3-ylmethoxy)quinazolin-4-yl]amino]-2-methylphenyl] acetate Chemical compound N1=CN=C2C=C(OCC=3C=NC=CC=3)C(OC)=CC2=C1NC1=CC=C(C)C(OC(C)=O)=C1 BQZQJUAMTWEOHY-UHFFFAOYSA-N 0.000 description 1
- INGYCBHIUAFYRQ-UHFFFAOYSA-N [5-[[6-methoxy-7-(pyridin-4-ylmethoxy)quinazolin-4-yl]amino]-2-methylphenyl] acetate Chemical compound N1=CN=C2C=C(OCC=3C=CN=CC=3)C(OC)=CC2=C1NC1=CC=C(C)C(OC(C)=O)=C1 INGYCBHIUAFYRQ-UHFFFAOYSA-N 0.000 description 1
- VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 description 1
- OALHUCDUEQFZOG-UHFFFAOYSA-N [6-methoxy-7-[2-[methyl-(6-methylpyrimidin-4-yl)amino]ethoxy]-4-oxoquinazolin-3-yl]methyl 2,2-dimethylpropanoate Chemical compound COC1=CC(C(N(COC(=O)C(C)(C)C)C=N2)=O)=C2C=C1OCCN(C)C1=CC(C)=NC=N1 OALHUCDUEQFZOG-UHFFFAOYSA-N 0.000 description 1
- PHFBBPOPQZPDNM-UHFFFAOYSA-N [7-[2-[2,2-dimethylpropanoyl(methyl)amino]ethoxy]-6-methoxy-4-oxoquinazolin-3-yl]methyl 2,2-dimethylpropanoate Chemical compound N1=CN(COC(=O)C(C)(C)C)C(=O)C2=C1C=C(OCCN(C)C(=O)C(C)(C)C)C(OC)=C2 PHFBBPOPQZPDNM-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical class C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000001740 anti-invasion Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- XCEUHXVTRJQJSR-UHFFFAOYSA-N bromo(phenyl)phosphane Chemical compound BrPC1=CC=CC=C1 XCEUHXVTRJQJSR-UHFFFAOYSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 125000005514 but-1-yn-3-yl group Chemical group 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- FCVCYPORNYEAAV-UHFFFAOYSA-N chloromethane;hydrochloride Chemical compound Cl.ClC FCVCYPORNYEAAV-UHFFFAOYSA-N 0.000 description 1
- GGRHYQCXXYLUTL-UHFFFAOYSA-N chloromethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCl GGRHYQCXXYLUTL-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate trihydrate Substances [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- RVZHVQZQEPMTQJ-UHFFFAOYSA-N ethanol;1h-imidazole Chemical class CCO.C1=CNC=N1 RVZHVQZQEPMTQJ-UHFFFAOYSA-N 0.000 description 1
- VGDZPGBZLGNFBF-UHFFFAOYSA-N ethyl 2-methoxypyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC(OC)=C1 VGDZPGBZLGNFBF-UHFFFAOYSA-N 0.000 description 1
- BTLPIHZIMJTFNH-UHFFFAOYSA-N ethyl 2-oxo-1h-pyridine-4-carboxylate Chemical compound CCOC(=O)C=1C=CNC(=O)C=1 BTLPIHZIMJTFNH-UHFFFAOYSA-N 0.000 description 1
- WPDFCSISXJTYIW-UHFFFAOYSA-N ethyl 4-(hydroxymethyl)pyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC(CO)=CC=N1 WPDFCSISXJTYIW-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 150000005699 fluoropyrimidines Chemical class 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 150000002343 gold Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- HHUNWJWOJPWLNK-UHFFFAOYSA-N methyl 2-methylpyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(C)=C1 HHUNWJWOJPWLNK-UHFFFAOYSA-N 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical class O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- ULIDQZITUSUWHW-UHFFFAOYSA-N n-(4-bromo-2-fluorophenyl)-6-methoxy-7-[2-(1,2,4-triazol-1-yl)ethoxy]quinazolin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCCN3N=CN=C3)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F ULIDQZITUSUWHW-UHFFFAOYSA-N 0.000 description 1
- NPXVXVIAEYTWER-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-(2-pyridin-3-ylethoxy)quinazolin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCCC=3C=NC=CC=3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F NPXVXVIAEYTWER-UHFFFAOYSA-N 0.000 description 1
- YCQLOUPEDBSNSS-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-(2-pyridin-4-ylethoxy)quinazolin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCCC=3C=CN=CC=3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F YCQLOUPEDBSNSS-UHFFFAOYSA-N 0.000 description 1
- HCGUEEDAMSYXJI-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-(3-pyridin-4-ylprop-2-enoxy)quinazolin-4-amine Chemical compound N1=CN=C2C=C(OCC=CC=3C=CN=CC=3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F HCGUEEDAMSYXJI-UHFFFAOYSA-N 0.000 description 1
- MLEKCFQCSCEMRZ-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-(pyridin-2-ylmethoxy)quinazolin-4-amine Chemical compound N1=CN=C2C=C(OCC=3N=CC=CC=3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F MLEKCFQCSCEMRZ-UHFFFAOYSA-N 0.000 description 1
- TURBIPGLFUVZPD-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-(pyridin-4-ylmethoxy)quinazolin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC=3C=CN=CC=3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F TURBIPGLFUVZPD-UHFFFAOYSA-N 0.000 description 1
- VSGKURNTUIFOTJ-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-(thiophen-3-ylmethoxy)quinazolin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC3=CSC=C3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F VSGKURNTUIFOTJ-UHFFFAOYSA-N 0.000 description 1
- GVOJLNCKUYCXME-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-[(2-methylpyridin-4-yl)methoxy]quinazolin-4-amine Chemical compound N1=CN=C2C=C(OCC=3C=C(C)N=CC=3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F GVOJLNCKUYCXME-UHFFFAOYSA-N 0.000 description 1
- RBGRWHPHMKAXKL-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(1,2,4-triazol-1-yl)ethoxy]quinazolin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCCN3N=CN=C3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F RBGRWHPHMKAXKL-UHFFFAOYSA-N 0.000 description 1
- KWOBVOJXXWJDLE-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(1,2,4-triazol-4-yl)ethoxy]quinazolin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCCN3C=NN=C3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F KWOBVOJXXWJDLE-UHFFFAOYSA-N 0.000 description 1
- OYARQJGOZRTOIV-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(2-methylimidazol-1-yl)ethoxy]quinazolin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCCN3C(=NC=C3)C)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F OYARQJGOZRTOIV-UHFFFAOYSA-N 0.000 description 1
- HBQFLOBIKOCQKJ-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(6-methylpyridin-2-yl)ethoxy]quinazolin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCCC=3N=C(C)C=CC=3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F HBQFLOBIKOCQKJ-UHFFFAOYSA-N 0.000 description 1
- RHCLAXBFYIAEEV-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(methylamino)ethoxy]quinazolin-4-amine;hydrate;hydrochloride Chemical compound O.Cl.C=12C=C(OC)C(OCCNC)=CC2=NC=NC=1NC1=CC=C(Cl)C=C1F RHCLAXBFYIAEEV-UHFFFAOYSA-N 0.000 description 1
- NPRVRSZRPTWNGH-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-(pyridin-4-ylamino)ethoxy]quinazolin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCCNC=3C=CN=CC=3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F NPRVRSZRPTWNGH-UHFFFAOYSA-N 0.000 description 1
- FLFYUPLIGAEODC-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-[2-[methyl(pyridazin-4-yl)amino]ethoxy]quinazolin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCCN(C)C=3C=NN=CC=3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F FLFYUPLIGAEODC-UHFFFAOYSA-N 0.000 description 1
- JOHNIYZRJXDVBV-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-phenylmethoxyquinazolin-4-amine;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC=3C=CC=CC=3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F JOHNIYZRJXDVBV-UHFFFAOYSA-N 0.000 description 1
- HWCIXYZDVOJGQJ-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-7-[2-[(2,6-dimethylpyridin-4-yl)-methylamino]ethoxy]-6-methoxyquinazolin-4-amine Chemical compound N1=CN=C2C=C(OCCN(C)C=3C=C(C)N=C(C)C=3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F HWCIXYZDVOJGQJ-UHFFFAOYSA-N 0.000 description 1
- AGJOAIMUXIQLCN-UHFFFAOYSA-N n-(4-methylphenyl)hydroxylamine Chemical compound CC1=CC=C(NO)C=C1 AGJOAIMUXIQLCN-UHFFFAOYSA-N 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- ZLBUACDRTQBLEL-UHFFFAOYSA-N n-[2-(4-chloro-6-methoxyquinazolin-7-yl)oxyethyl]-n,6-dimethylpyrimidin-4-amine Chemical compound COC1=CC2=C(Cl)N=CN=C2C=C1OCCN(C)C1=CC(C)=NC=N1 ZLBUACDRTQBLEL-UHFFFAOYSA-N 0.000 description 1
- NBUKMHXINQOFDI-UHFFFAOYSA-N n-[4-(chloromethyl)-1,3-thiazol-2-yl]acetamide Chemical compound CC(=O)NC1=NC(CCl)=CS1 NBUKMHXINQOFDI-UHFFFAOYSA-N 0.000 description 1
- HEHSEBKIHUALBC-UHFFFAOYSA-N n-[4-[[4-(2-fluoro-5-hydroxy-4-methylanilino)-6-methoxyquinazolin-7-yl]oxymethyl]-1,3-thiazol-2-yl]acetamide Chemical compound N1=CN=C2C=C(OCC=3N=C(NC(C)=O)SC=3)C(OC)=CC2=C1NC1=CC(O)=C(C)C=C1F HEHSEBKIHUALBC-UHFFFAOYSA-N 0.000 description 1
- DHBQOHJEQGKMQD-UHFFFAOYSA-N n-[4-[[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxymethyl]-1,3-thiazol-2-yl]acetamide;hydrochloride Chemical compound Cl.N1=CN=C2C=C(OCC=3N=C(NC(C)=O)SC=3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F DHBQOHJEQGKMQD-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- ICBYIKRIEVEFCX-UHFFFAOYSA-N oxan-2-amine Chemical compound NC1CCCCO1 ICBYIKRIEVEFCX-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- REJGOFYVRVIODZ-UHFFFAOYSA-N phosphanium;chloride Chemical compound P.Cl REJGOFYVRVIODZ-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960003522 roquinimex Drugs 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- VLFAFNPKIPOTPC-UHFFFAOYSA-M sodium acetyl acetate hydroxide Chemical compound C(C)(=O)OC(C)=O.[OH-].[Na+] VLFAFNPKIPOTPC-UHFFFAOYSA-M 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- RFDSJHHLGFFVHD-UHFFFAOYSA-N tert-butyl n-(2-hydroxyethyl)-n-methylcarbamate Chemical compound OCCN(C)C(=O)OC(C)(C)C RFDSJHHLGFFVHD-UHFFFAOYSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- WAOWQLJJQBDGQC-UHFFFAOYSA-N tetraazanium;tetrafluoride Chemical compound [NH4+].[NH4+].[NH4+].[NH4+].[F-].[F-].[F-].[F-] WAOWQLJJQBDGQC-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000010938 white gold Chemical class 0.000 description 1
- 229910000832 white gold Inorganic materials 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.以下の式Iのキナゾリン誘導体およびその塩: [ここで: Y1は、-O-、-S-、-CH2-、-SO-、-SO2-、-NR5CO-、-CONR6-、-SO2NR7-、-NR8SO2- または-NR9-を表す(ここで、R5、R6、R7、R8およびR9は、それぞれ独立して、 水素、C1 〜3アルキルまたはC1 〜3アルコキシC2 〜3アルキルを表す); R1は、水素、ヒドロキシ、ハロゲノ、ニトロ、トリフルオロメチル、シアノ、C1 〜3 アルキル、C1 〜3アルコキシ、C1 〜3アルキルチオ、またはNR10R11を表す(こ こで、R10およびR11は、同じであるかまたは異なり得、それぞれ独立して、水素 またはC1 〜3アルキルを表す); R2は、水素、ヒドロキシ、ハロゲノ、C1 〜3アルキル、C1 〜3アルコキシ、トリフ ルオロメチル、シアノ、アミノ、またはニトロを表す; mは、1〜5の整数である; R3は、ヒドロキシ、ハロゲノ、C1 〜3アルキル、C1 〜3アルコキシ、C1 〜3アルカ ノイルオキシ、トリフルオロメチル、シアノ、アミノ、またはニトロを表す; R4は、以下の8つの群の1つから選択される: 1)X1(ここで、X1は、ピリドン基、フェニル基またはO、NおよびSから選択さ れる1〜3個のヘテロ原子を有する5員もしくは6員の芳香族ヘテロ環基を表し 、このピリドン基、フェニル基またはヘテロ環基は、ハロゲノ、アミノ、C1 〜4 ア ルキル、C1 〜4アルコキシ、C1 〜4ヒドロキシアルキル、C1 〜4アミノアルキル、C1 〜4 アルキルアミノ、C1 〜4ヒドロキシアルコキシ、カルボキシ、シアノ、-CONR12 R13および-NR14COR15から選択される5つまでの置換基を有し得る(ここで、R12 、R13、R14およびR15は、同じであるかまたは異なり得、それぞれ独立して、 水素、C1 〜4アルキルまたはC1 〜3アルコキシC2 〜3アルキルを表す)); 2)C1 〜5アルキルX1(ここで、X1は、上記に定義した通りである); 3)C2 〜5アルケニルX1(ここで、X1は、上記に定義した通りである); 4)C2 〜5アルキニルX1(ここで、X1は、上記に定義した通りである); 5)C1 〜5アルキルY2X1(ここで、Y2は、-O-、-S-、-SO-、-SO2-、-OCO-、-NR16 CO-、-CONR17-、-SO2NR18-、-NR19SO2-または-NR20-を表し(ここで、R16、R17 、R18、R19およびR20は、それぞれ独立して、水素、C1 〜3アルキルまたはC1 〜3 アルコキシC2 〜3アルキルを表す)、およびX1は、上記に定義した通りである) ; 6)C2 〜5アルケニルY3X1(ここで、Y3は、-O-、-S-、-SO-、-SO2-、-OCO-、-NR21 CO-、-CONR22-、-SO2NR23-、-NR24SO2-または-NR25-を表し(ここで、R21、R2 2 、R23、R24およびR25は、それぞれ独立して、水素、C1 〜3アルキルまたはC1 〜3 アルコキシC2 〜3アルキルを表す)、およびX1は、上記に定義した通りである) ; 7)C2 〜5アルキニルY4X1(ここで、Y4は、-O-、-S-、-SO-、-SO2-、-OCO-、-NR26 CO-、-CONR27-、-SO2NR28-、-NR29SO2-または-NR30-を表し(ここで、R26、R2 7 、R28、R29およびR30は、それぞれ独立して、水素、C1 〜3アルキルまたはC1 〜3 アルコキシC2 〜3アルキルを表す)、およびX1は、上記に定義した通りである) ;および 8)C1 〜3アルキルY5C1 〜3アルキルX1(ここで、Y5は、-O-、-S-、-SO-、-SO2- 、-NR31CO-、-CONR32-、-SO2NR33-、-NR34SO2-または-NR35-を表し(ここで、R3 1 、R32、R33、R34およびR35は、それぞれ独立して、水素、C1 〜3アルキルまたは C1 〜3アルコキシC2 〜3アルキルを表す)、およびX1は、上記に定義した通りであ る);Zは、-NH-、-O-、-S-または-CH2-を表す;ただし、R4が、上記1)、2) および5)の群のうちの1つから選択され、かつX1が、非置換のフェニル、また はハロゲノ、C1 〜4アルキルおよびC1 〜4アルコキシから選択される1〜2つの置 換基によって置換されたフェニルである場合、mは3〜5の整数であり、および/ またはZは、-O-、-S-または-CH2-である]。 2.前記R1が、水素、ヒドロキシ、メチル、エチル、メトキシまたはエトキシを 表す、請求項1に記載のキナゾリン誘導体。 3.前記R2が、水素である、請求項1または2に記載のキナゾリン誘導体。 4.前記(R3)mを有するフェニル基が、以下の式IIa: (ここで、 Raは、水素、メチル、フルオロまたはクロロを表す; Rbは、水素、メチル、メトキシ、ブロモ、フルオロまたはクロロを表す; Rcは、水素またはヒドロキシを表す;および Rdは、水素、フルオロまたはクロロを表す)である、請求項1〜3のいずれか1 項に記載のキナゾリン誘導体。 5.前記Zが、NHである、請求項1〜4のいずれか1項に記載のキナゾリン誘導 体。 6.前記Y1が、-O-、-S-、-CH2-、-NR5CO-、-NR8SO2-または-NH-を表す(ここで 、R5およびR8は、それぞれ独立して、水素、C1 〜2アルキルまたはC1 〜2アルコキ シエチルを表す)、請求項1〜5のいずれか1項に記載のキナゾリン誘導体。 7.前記R4基のX1部分が、ピリドン基またはO、NおよびSから選択される1〜3 個のヘテロ原子を有する5員もしくは6員の芳香族ヘテロ環基を表し、該ピリド ンまたはヘテロ環基は、所望であるならば、請求項1に定義したように置換され 得る、請求項1〜6のいずれか1項に記載のキナゾリン誘導体。 8.前記X1部分が、ピリドン基、ピリジル基、イミダゾリル基、チアゾリル基、 チエニル基、トリアゾリル基またはピリダジニル基を表し、それらは、所望であ るならば、請求項1に定義したように置換され得る、請求項7に記載のキナゾリ ン誘導体。 9.前記R4が、X1-Y6-(CH2)n-基を表し、該Y6が、-O-、-S-または-NH-に直接結 合し、nは、1〜3の整数であり、そしてX1が、請求項1、7および8のいずれ か1項に定義した通りである、請求項1〜8のいずれか1項に記載のキナゾリン 誘導体。 10.以下から選択される、請求項1に記載のキナゾリン誘導体およびその塩: 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-(2-(4-ピリジルオキシ )エトキシ)キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-[2-(4-オキソ-1,4- ジヒドロ-1-ピリジル)エトキシ]キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-7-(2-(イミダゾール-1-イル)エトキシ )-6-メトキシキナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-(3-(4-ピリジル)プロ ポキシ)キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-(2-(4-ピリジル)エト キシ)キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-((4-ピリジル)メトキシ )キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-(2-(2-メチルイミダゾ ール-1-イル)エトキシ)キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-(2-(1-メチルイミダゾ ール-2-イルチオ)エトキシ)キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-(2-(1,2,4-トリアゾ ール-1-イル)エトキシ)キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-(2-(N-(4-ピリジル)ア ミノ)エトキシ)キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-(2-(1-メチルイミダゾ ール-2-イル)エトキシ)キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-7-((2-シアノ-4-ピリジル)メトキシ)- 6-メトキシキナゾリン。 11.以下から選択される、請求項1に記載のキナゾリン誘導体およびその塩: 4-(3-ヒドロキシ-4-メチルアニリノ)-6-メトキシ-7-(4-ピリジルメトキシ )キナゾリン 4-(3-ヒドロキシ-4-メチルアニリノ)-6-メトキシ-7-(2-ピリジルメトキシ )キナゾリン 4-(3-ヒドロキシ-4-メチルアニリノ)-6-メトキシ-7-(1-メチルイミダゾー ル-2-イルメトキシ)キナゾリン 4-(3-ヒドロキシ-4-メチルアニリノ)-6-メトキシ-7-(2-メチルチアゾール -4-イルメトキシ)キナゾリン 7-(2-アセトアミドチアゾール-4-イルメトキシ)-4-(3-ヒドロキシ-4-メチ ルアニリノ)-6-メトキシキナゾリン 4-(3-ヒドロキシ-4-メチルアニリノ)-6-メトキシ-7-(4-ピリジルプロポキ シ)キナゾリン 4-(2-フルオロ-5-ヒドロキシ-4-メチルアニリノ)-6-メトキシ-7-(4-ピリ ジルプロポキシ)キナゾリン 4-(2-フルオロ-5-ヒドロキシ-4-メチルアニリノ)-6-メトキシ-7-(4-ピリ ジルメトキシ)キナゾリン 7-ベンジルオキシ-4-(2-フルオロ-5-ヒドロキシ-4-メチルアニリノ)-6-メ トキシキナゾリン 7-ベンジルオキシ-4-(2-フルオロ-5-ヒドロキシ-4-メチルフェノキシ)-6- メトキシキナゾリン 4-(2-フルオロ-5-ヒドロキシ-4-メチルアニリノ)-6-メトキシ-7-((2-メ チルチアゾール-4-イル)メトキシ)キナゾリン 4-(2-フルオロ-5-ヒドロキシ-4-メチルアニリノ)-7-(4-ピリジルメトキシ )キナゾリン 4-(2-フルオロ-5-ヒドロキシ-4-メチルアニリノ)-6-メトキシ-7-((1-メ チルイミダゾール-2-イル)メトキシ)キナゾリン 7-((2-アセタミドチアゾール-4-イル)メトキシ)-4-(2-フルオロ-5-ヒドロ キシ-4-メチルアニリノ)-6-メトキシキナゾリン 7-ベンジルオキシ-4-(4-クロロ-2-フルオロ-5-ヒドロキシアニリノ)-6-メ トキシキナゾリン 4-(4-クロロ-2-フルオロ-5-ヒドロキシアニリノ)-6-メトキシ-7-(3-(4- ピリジル)プロポキシ)キナゾリン 4-(2-フルオロ-5-ヒドロキシ-4-メチルアニリノ)-7-(2-(イミダゾール-1 -イル)エトキシ)-6-メトキシキナゾリン 4-(4-クロロ-2-フルオロ-5-ヒドロキシアニリノ)-7-(2-(イミダゾール-1 -イル)エトキシ)-6-メトキシキナゾリン 4-(2-フルオロ-5-ヒドロキシ-4-メチルアニリノ)-6-メトキシ-7-(2-(4- ピリジル)エトキシ)キナゾリン 4-(2-フルオロ-5-ヒドロキシ-4-メチルアニリノ)-6-メトキシ-7-(3-チエ ニルメトキシ)キナゾリン 4-(3-ヒドロキシ-4-メチルアニリノ)-6-メトキシ-7-((1-メチルベンズイ ミダゾール-2-イル)メトキシ)キナゾリン 7-((2-クロロ-6-メチル-4-ピリジル)メトキシ)-4-(2-フルオロ-5-ヒドロ キシ-4-メチルアニリノ)-6-メトキシキナゾリン 4-(4-クロロ-2-フルオロフェノキシ)-6-メトキシ-7-((4 ピリジル)メトキ シ)キナゾリン 4-(4-クロロ-2-フルオロ-5-ヒドロキシアニリノ)-6-メトキシ-7-((4 ピ リジル)メトキシ)キナゾリン 7-((2-クロロ-4-ピリジル)メトキシ)-4-(2-フルオロ-5-ヒドロキシ-4-メ チルアニリノ)-6-メトキシキナゾリン 7-(3,4-ジフルオロベンジルオキシ)-4-(2-フルオロ-5-ヒドロキシ-4-メ チルアニリノ)-6-メトキシキナゾリン 4-(4-クロロ-2-フルオロ-5-ヒドロキシアニリノ)-6-メトキシ-7-((1-メ チルイミダゾール-2-イル)メトキシ)キナゾリン 4-(2-フルオロ-5-ヒドロキシ-4-メチルアニリノ)-7-((1-メチルイミダゾ ール-2-イル)メトキシ)キナゾリン 4-(2-フルオロ-5-ヒドロキシ-4-メチルアニリノ)-7-(2-(1,2,4-トリア ゾール-1-イル)エトキシ)キナゾリン 4-(4-クロロ-2-フルオロ-5-ヒドロキシアニリノ)-6-メトキシ-7-((3-チ エニル)メトキシ)キナゾリン 4-(4-クロロ-2-フルオロ-5-ヒドロキシアニリノ)-6-メトキシ-7-(2-(4- ピリジル)エトキシ)キナゾリン 4-(2-フルオロ-5-ヒドロキシ-4-メチルアニリノ)-7-((4-ピリジル)カルボ キサミド)キナゾリン。 12.以下から選択される、請求項1に記載のキナゾリン誘導体およびその塩: 4-(3-ヒドロキシ-4-メチルアニリノ)-6-メトキシ-7-(3-ピリジルメトキシ )キナゾリン 4-(3-ヒドロキシ-4-メチルアニリノ)-6-メトキシ-7-(3-チエニルメトキシ )キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-(2-(2-ピリジルオキシ )エトキシ)キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-(2-[(N-メチル-N-(4- ピリジル)]アミノエトキシ)キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-[2-(2-オキソ-1,2- ジヒドロ-1-ピリジル)エトキシ]キナゾリン 7-(4 シアノベンジルオキシ)-4-(2-フルオロ-5-ヒドロキシ-4-メチルアニ リノ)-6-メトキシキナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-(3-(2-メチルイミダゾ ール-1-イル)プロポキシ)キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-((2-メチル-4-ピリジ ル)メトキシ)キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-(3-(2-オキソ-1,2- ジヒドロ-1-ピリジル)プロポキシ)キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-(3-(1-メチルイミダゾ ール-2-イルチオ)プロポキシ)キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-(3-(4-ピリジルオキシ )プロポキシ)キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-(2-(4-ピリジルチオ) エトキシ)キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-(2-(3-ピリジルオキシ )エトキシ)キナゾリン 7-ベンジルオキシ-4-(2-フルオロ-5-ヒドロキシ-4-メチルアニリノ)キナゾ リン 7-ベンジルオキシ-4-(4-クロロ-2-フルオロ-5-ヒドロキシアニリノ)キナゾ リン 4-(4-クロロ-2-フルオロ-5-ヒドロキシアニリノ)-6-メトキシ-7-((2-メ チルチアゾール-4-イル)メトキシ)キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-((3-チエニル)メトキシ )キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-(2-(N-メチル-N-(ピリ ダジン-4-イル)アミノ)エトキシ)キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-(2-(N-メチル-N-(6-メ チルピリミジン-4-イル)アミノ)エトキシ)キナゾリン 4-(4-クロロ-2-フルオロアニリノ)-7-(2-(3,5-ジメチル-[1,2,4]-ト リアゾール-4-イル)エトキシ)-6-メトキシキナゾリン 4-(4-クロロ-2-フルオロアニリノ)-7-(2-(2,4-ジメチルイミダゾール-1 -イル)エトキシ)-6-メトキシキナゾリン 4-(4-クロロ-2-フルオロアニリノ)-7-(2-(2,5-ジメチルイミダゾール-1 -イル)エトキシ)-6-メトキシキナゾリン 4-(3-ヒドロキシアニリノ)-7-(2-(イミダゾール-1-イル)エトキシ)-6-メ トキシキナゾリン 4-(4-クロロ-2-フルオロアニリノ)-6-メトキシ-7-(2-(1,2,4-トリアゾ ール-4-イル)エトキシ)キナゾリン 4-(4-ブロモ-2-フルオロアニリノ)-7-(2-([1,2,4]-トリアゾール-1-イ ル)エトキシ)-6-メトキシキナゾリン。 13.薬学的に受容可能な塩の形態である、請求項1〜12のいずれか1項に記 載のキナゾリン誘導体。 14.請求項1で定義した式Iのキナゾリン誘導体またはその塩の調製プロセス であって、該プロセスは以下の工程: (a)以下の式IIIの化合物: (ここで、R1、R2、R4およびY1は、請求項1に定義した通りであり、そしてL1は 、置換可能な基を表す)と、式IVの化合物: (ここで、Z、R3およびmは、請求項1に定義した通りである)とを反応させ、該 反応により式Iの化合物およびその塩を得る工程; (b)式Iの化合物およびその塩であって、ここで、以下の式IIbの基: (ここで、R3およびmは、請求項1に定義した通りである)が、1つ以上のヒド ロキシ基を有するフェニル基を表す場合、該化合物およびその塩を調製するため に、以下の式Vの化合物: (ここで、Y1、m、R1、R2、R3、R4およびZは、請求項1に定義した通りであり、 Pは、フェノール性ヒドロキシ保護基を表し、そしてp1は、保護されたヒドロキ シ基の数と等しい1〜5の整数であり、その結果、m-p1は、保護されたヒドロキ シではないR3置換基の数と等しくなる)を脱保護する工程; (c)前記置換基Y1が-O-、-S-または-NR9-である式Iの化合物およびその塩を調 製するために、以下の式VIの化合物: (ここで、m、Y1、R1、R2、R3およびZは、請求項1に定義した通りである)と、 以下の式VIIの化合物: R4-L1 (VII) (ここで、R4は、請求項1に定義した通りであり、そしてL1は、上記に定義した 通りである)とを反応させる工程; (d)以下の式VIIIの化合物: (ここで、R1、R2、R3、Zおよびmは、請求項1に定義した通りであり、そしてL1 は、上記に定義した通りである)と、以下の式IXの化合物: R4-Y1-H (IX) (ここで、R4およびY1は、請求項1に定義した通りである)とを反応させる工程 ; (e)式Iの化合物およびその塩であって、ここで、R4が、C1 〜5アルキルX2、[こ こで、X2は、以下の3つの群の1つから選択される: 1)X1(ここで、X1は、請求項1に定義した通りである); 2)Y7X1(ここで、Y7は、-O-、-S-、-SO2-、-NR47CO-、-NR48SO2-または-NR49- を表し(ここで、R47、R48およびR49は、それぞれ独立して、水素、C1 〜3アルキ ルまたはC1 〜3アルコキシC2 〜3アルキルを表す)、そしてX1は、請求項1に定義 した通りである);および 3)Y8C1 〜5アルキルY5X1(ここで、Y8は、-O-、-S-、-SO2-、-NR50CO-、-NR51S O2-または-NR52-を表し(ここで、R50、R51およびR52は、それぞれ独立して、水 素、C1 〜3アルキルまたはC1 〜3アルコキシC2 〜3アルキルを表す)、そしてY5お よびX1は、請求項1に定義した通りである);]である、該化合物およびその塩 を調製するために、以下の式Xの化合物:(ここで、Y1、R1、R2、R3、Zおよびmは、請求項1に定義した通りであり、L1は 、上記に定義した通りであり、そしてR53は、C1 〜5アルキルを表す)と、以下の 式XIの化合物: X2-H (XI) (ここで、X2は、上記に定義した通りである)とを反応させ、式Iの化台物を提 供する工程; (f)置換基R1がNR10R11により表され、ここで、R10およびR11の1つまたは両方 がC1 〜3アルキルである、式Iの化合物およびその塩を調製するために、置換基R1 がアミノ基である式Iの化合物と、アルキル化剤とを反応させる工程; (g)置換基R1、R2またはR3の1つ以上がアミノ基である、式Iの化合物およびそ の塩を調製するために、キナゾリン環および/またはフェニル環の対応する位置 (単数または複数)の置換基(単数または複数)が、ニトロ基(単数または複数 )である、式Iの対応する化合物を還元する工程;および式Iのキナゾリン誘導体 の薬学的に受容可能な塩が必要とされる場合、得られた化合物と、酸または塩基 とを反応させ、該反応により所望の薬学的に受容可能な塩を得る、工程を包含す る、プロセス。 15.薬学的に受容可能な賦形剤またはキャリアと共に請求項1に定義した通り である式Iのキナゾリン誘導体またはその薬学的に受容可能な塩を活性成分とし て含む、薬学的組成物。 16.抗脈管形成および/または血管透過性を低減する効果を、そのような処置 が必要とされる温血動物において引き起こすための方法であって、該動物に請求 項1に定義した通りである式Iの化合物またはその薬学的に受容可能な塩の有効 量を投与する工程を含む、方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95402846 | 1995-12-18 | ||
EP95402846.0 | 1995-12-18 | ||
EP96402190.1 | 1996-10-15 | ||
EP96402190 | 1996-10-15 | ||
PCT/GB1996/003075 WO1997022596A1 (en) | 1995-12-18 | 1996-12-13 | Quinazoline derivatives |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008183259A Division JP2009007364A (ja) | 1996-10-15 | 2008-07-14 | キナゾリン誘導体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2000515114A true JP2000515114A (ja) | 2000-11-14 |
JP2000515114A5 JP2000515114A5 (ja) | 2004-11-04 |
JP4291413B2 JP4291413B2 (ja) | 2009-07-08 |
Family
ID=26140602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52256897A Expired - Fee Related JP4291413B2 (ja) | 1995-12-18 | 1996-12-13 | キナゾリン誘導体 |
Country Status (29)
Country | Link |
---|---|
US (4) | US5962458A (ja) |
EP (1) | EP0873319B1 (ja) |
JP (1) | JP4291413B2 (ja) |
KR (1) | KR100530311B1 (ja) |
CN (1) | CN1133625C (ja) |
AT (1) | ATE203524T1 (ja) |
AU (1) | AU712370B2 (ja) |
BR (1) | BR9612043A (ja) |
CA (1) | CA2237005C (ja) |
CZ (1) | CZ291100B6 (ja) |
DE (1) | DE69614147T2 (ja) |
DK (1) | DK0873319T3 (ja) |
ES (1) | ES2162656T3 (ja) |
GB (1) | GB9624482D0 (ja) |
GR (1) | GR3036954T3 (ja) |
HU (1) | HUP9901243A3 (ja) |
IL (1) | IL124925A0 (ja) |
MX (1) | MX9804247A (ja) |
MY (1) | MY132405A (ja) |
NO (1) | NO311358B1 (ja) |
NZ (1) | NZ324007A (ja) |
PL (1) | PL192309B1 (ja) |
PT (1) | PT873319E (ja) |
RU (1) | RU2194701C2 (ja) |
SI (1) | SI0873319T1 (ja) |
SK (1) | SK282443B6 (ja) |
TR (1) | TR199801115T2 (ja) |
TW (1) | TW411274B (ja) |
WO (1) | WO1997022596A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003073356A (ja) * | 2001-08-30 | 2003-03-12 | Koei Chem Co Ltd | メチルヒドロキシアルキルピリジン類の製造方法 |
WO2005080377A1 (ja) * | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
JPWO2004018430A1 (ja) * | 2002-08-23 | 2005-12-08 | 麒麟麦酒株式会社 | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
JP2007518824A (ja) * | 2004-01-23 | 2007-07-12 | アムゲン インコーポレイテッド | 化合物及び使用方法 |
JP2017526668A (ja) * | 2014-08-11 | 2017-09-14 | 石薬集団中奇制薬技術(石家庄)有限公司 | キナゾリン誘導体 |
Families Citing this family (527)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6228871B1 (en) | 1995-07-10 | 2001-05-08 | Merck & Co., Inc. | Angiogenesis inhibitors |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
KR19990082463A (ko) | 1996-02-13 | 1999-11-25 | 돈 리사 로얄 | 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체 |
WO1997032856A1 (en) | 1996-03-05 | 1997-09-12 | Zeneca Limited | 4-anilinoquinazoline derivatives |
NZ332119A (en) | 1996-04-12 | 2001-08-31 | Warner Lambert Co | Quinazoline compounds which are irreversible inhibitors of tyrosine kinases |
GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
RU2190611C2 (ru) | 1996-06-27 | 2002-10-10 | Жансен Фармасетика Н.В. | N-[4-(гетероарилметил)фенил]-гетероариламины |
AU733551B2 (en) | 1996-09-25 | 2001-05-17 | Astrazeneca Ab | Qinoline derivatives inhibiting the effect of growth factors such as VEGF |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
JP2009007364A (ja) * | 1996-10-15 | 2009-01-15 | Astrazeneca Uk Ltd | キナゾリン誘導体 |
US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
ZA986729B (en) * | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
JP4959049B2 (ja) | 1997-08-22 | 2012-06-20 | アストラゼネカ・ユーケイ・リミテッド | 血管新生阻害剤としてのオキシインドリルキナゾリン誘導体 |
US6465484B1 (en) | 1997-09-26 | 2002-10-15 | Merck & Co., Inc. | Angiogenesis inhibitors |
US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
FR2772763B1 (fr) * | 1997-12-24 | 2004-01-23 | Sod Conseils Rech Applic | Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant |
US6686366B1 (en) | 1998-06-02 | 2004-02-03 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
MXPA00011889A (es) | 1998-06-02 | 2003-04-25 | Osi Pharm Inc | Composiciones de pirrolo (2,3d) piridina y su uso. |
US6878716B1 (en) | 1998-06-02 | 2005-04-12 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptor and uses thereof |
US20040067227A1 (en) * | 2001-11-02 | 2004-04-08 | Goldstein Allan L. | Inhibition or reversal of skin aging by actin-sequestering peptides |
JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
EP1154774B1 (en) * | 1999-02-10 | 2005-06-22 | AstraZeneca AB | Quinazoline derivatives as angiogenesis inhibitors |
AU5003200A (en) | 1999-05-14 | 2000-12-05 | United States Of America As Represented By The Department Of Veterans Affairs, The | Isolation and characterization of epidermal growth factor related protein |
US7049410B2 (en) * | 1999-05-14 | 2006-05-23 | Majumdar Adhip P N | Antibodies to a novel EGF-receptor related protein (ERRP) |
EP1194418A1 (de) * | 1999-06-21 | 2002-04-10 | Boehringer Ingelheim Pharma KG | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
AU7301000A (en) * | 1999-09-21 | 2001-04-24 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
KR20020032608A (ko) * | 1999-09-21 | 2002-05-03 | 다비드 에 질레스 | 퀴나졸린 화합물 및 이를 함유하는 제약 조성물 |
SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
SK287401B6 (sk) | 1999-11-05 | 2010-09-07 | Astrazeneca Ab | Deriváty chinazolínu, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie |
UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
AU4903201A (en) | 1999-11-30 | 2001-07-03 | Parker Hughes Institute | Inhibitors of thrombin induced platelet aggregation |
US6664252B2 (en) | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
US7160890B2 (en) * | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
WO2001057008A1 (en) | 2000-02-07 | 2001-08-09 | Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
AUPQ592100A0 (en) * | 2000-02-29 | 2000-03-23 | Council Of The Queensland Institute Of Medical Research, The | A method of treatment and prophylaxis |
JP2003525897A (ja) | 2000-03-06 | 2003-09-02 | アストラゼネカ アクチボラグ | 治 療 |
US20070021392A1 (en) * | 2000-03-31 | 2007-01-25 | Davis Peter D | Divided dose therapies with vascular damaging activity |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
EP1274692B1 (en) * | 2000-04-07 | 2006-08-02 | AstraZeneca AB | Quinazoline compounds |
UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
NZ523702A (en) | 2000-08-21 | 2004-08-27 | Astrazeneca Ab | Quinazoline derivatives |
DE10042058A1 (de) * | 2000-08-26 | 2002-03-07 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6656946B2 (en) | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
PT1313734E (pt) | 2000-09-01 | 2010-02-09 | Novartis Vaccines & Diagnostic | Derivados aza heterocíclicos e sua utilização terapêutica |
US20030028018A1 (en) * | 2000-09-11 | 2003-02-06 | Chiron Coporation | Quinolinone derivatives |
DK1650203T3 (da) * | 2000-09-11 | 2008-06-02 | Novartis Vaccines & Diagnostic | Quinolinonderivater som tyrosinkinaseinhibitorer |
SE0003828D0 (sv) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
DE60144284D1 (de) | 2000-11-01 | 2011-05-05 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
AU2001229722A1 (en) * | 2000-11-29 | 2002-06-11 | Parker Hughes Institute | Inhibitors of thrombin induced platelet aggregation |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
US7019012B2 (en) * | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
DK2311825T3 (en) | 2000-12-21 | 2016-01-18 | Novartis Ag | Pyrimidinamines AS ANGIOGENESEMODULATORER |
NZ569856A (en) | 2001-01-05 | 2010-03-26 | Pfizer | Antibodies to insulin-like growth factor 1 receptor |
US20070050857A1 (en) * | 2001-02-28 | 2007-03-01 | Hayward Nick K | Method of treatment and prophylaxis |
MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
WO2002092578A1 (en) * | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
AU2002350105A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
WO2003000194A2 (en) | 2001-06-21 | 2003-01-03 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
CA2465068A1 (en) * | 2001-11-03 | 2003-05-15 | Astrazeneca Ab | Quinazoline derivatives as antitumor agents |
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
DK1450811T3 (da) * | 2001-11-30 | 2010-02-15 | Osi Pharm Inc | Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf |
ATE519748T1 (de) * | 2001-12-19 | 2011-08-15 | Ube Industries | Verfahren zur herstellung von chinazolin-4-on und derivaten davon |
US20030229067A1 (en) * | 2001-12-20 | 2003-12-11 | Arlindo Castelhano | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use |
JP4440642B2 (ja) | 2001-12-20 | 2010-03-24 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | ピリミジンA2b選択的アンタゴニスト化合物、それらの合成、及び使用 |
US8367824B2 (en) * | 2002-01-28 | 2013-02-05 | Ube Industries Ltd. | Process for producing quinazolin-4-one derivative |
RU2362775C1 (ru) * | 2002-02-01 | 2009-07-27 | Астразенека Аб | Хиназолиновые соединения |
AU2003206068A1 (en) | 2002-03-01 | 2003-09-16 | Pfizer Inc. | Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents |
TWI324597B (en) * | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
DE10221018A1 (de) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
UA77303C2 (en) | 2002-06-14 | 2006-11-15 | Pfizer | Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use |
US6936641B2 (en) * | 2002-06-25 | 2005-08-30 | Johnson & Johnson Vision Care, Inc. | Macromer forming catalysts |
EP1521747B1 (en) | 2002-07-15 | 2018-09-05 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
US20050256157A1 (en) * | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
US7825132B2 (en) * | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
WO2004018419A2 (en) * | 2002-08-23 | 2004-03-04 | Chiron Corporation | Benzimidazole quinolinones and uses thereof |
AU2003255819A1 (en) | 2002-08-24 | 2004-03-11 | Astrazeneca Ab | Pyrimidine derivatives as modulators of chemokine receptor activity |
GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
RU2350618C2 (ru) * | 2002-11-04 | 2009-03-27 | Астразенека Аб | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ |
SG148864A1 (en) * | 2002-11-13 | 2009-01-29 | Chiron Corp | Methods of treating cancer and related methods |
BR0317548A (pt) | 2002-12-19 | 2005-11-22 | Pfizer | Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso |
ATE370958T1 (de) | 2002-12-24 | 2007-09-15 | Astrazeneca Ab | Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung |
US7223749B2 (en) * | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
AP2114A (en) | 2003-02-26 | 2010-03-04 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
GB0318423D0 (en) * | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
EP2281885A1 (en) | 2003-08-27 | 2011-02-09 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
DE602004017479D1 (de) | 2003-08-29 | 2008-12-11 | Pfizer | Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon |
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
MXPA06002964A (es) | 2003-09-16 | 2006-06-14 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de cinasa de tirosina. |
JP2007505873A (ja) * | 2003-09-16 | 2007-03-15 | アストラゼネカ アクチボラグ | チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
NZ545913A (en) * | 2003-09-19 | 2009-01-31 | Astrazeneca Ab | Quinazoline derivatives |
ATE353888T1 (de) * | 2003-09-19 | 2007-03-15 | Astrazeneca Ab | Chinazolinderivate |
KR20060100388A (ko) * | 2003-09-25 | 2006-09-20 | 아스트라제네카 아베 | 퀴나졸린 유도체 |
EP1673085B1 (en) * | 2003-09-26 | 2011-11-09 | Exelixis, Inc. | C-met modulators and methods of use |
US7456189B2 (en) | 2003-09-30 | 2008-11-25 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
SG132683A1 (en) * | 2003-10-15 | 2007-06-28 | Osi Pharm Inc | Imidazopyrazine tyrosine kinase inhibitors |
JP4823914B2 (ja) | 2003-11-07 | 2011-11-24 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Fgfr3の阻害および多発性骨髄腫の治療 |
GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
CA2546486A1 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
GB0328243D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
UA82577C2 (en) | 2003-12-23 | 2008-04-25 | Пфайзер Инк. | Quinoline derivatives |
GB0330002D0 (en) | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
EP1732920B1 (en) | 2004-01-05 | 2011-03-09 | AstraZeneca AB | Thiophene derivatives as chk 1 inhibitors |
CN1960731B (zh) * | 2004-02-20 | 2011-12-07 | 诺华疫苗和诊断公司 | 调节炎性和转移过程的方法 |
DK1740591T3 (da) | 2004-04-02 | 2009-10-26 | Osi Pharm Inc | Heterobicykliske proteinkinaseinhibitorer substitueret med en 6,6-biocyclisk ring |
DK1746999T3 (da) | 2004-05-06 | 2012-01-23 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amider |
EP1756088A1 (en) * | 2004-06-04 | 2007-02-28 | AstraZeneca AB | Quinazoline derivatives as erbb receptor tyrosine kinases |
SE0401657D0 (sv) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
CN101014365B (zh) | 2004-07-16 | 2011-04-13 | 辉瑞产品公司 | 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤 |
TW200613306A (en) | 2004-07-20 | 2006-05-01 | Osi Pharm Inc | Imidazotriazines as protein kinase inhibitors |
RS51362B (en) | 2004-08-26 | 2011-02-28 | Pfizer Inc. | ENANTIOMERALLY PURE AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS |
PL1809624T3 (pl) | 2004-08-28 | 2014-03-31 | Astrazeneca Ab | Pochodne pirymidynosulfonoamidu jako modulatory receptora chemokinowego |
EP1827434B1 (en) | 2004-11-30 | 2014-01-15 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
ATE501148T1 (de) | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
AU2005319382B2 (en) | 2004-12-21 | 2011-04-07 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
GB0428526D0 (en) | 2004-12-30 | 2005-02-09 | Novartis Ag | Organic compounds |
AU2006208012B2 (en) * | 2005-01-27 | 2011-08-04 | Novartis Vaccines And Diagnostics Inc. | Treatment of metastasized tumors |
PT1846394E (pt) | 2005-02-04 | 2012-01-05 | Astrazeneca Ab | Derivados de pirazolilaminopiridina úteis como inibidores da quinase |
DK1854789T3 (da) * | 2005-02-23 | 2013-10-21 | Shionogi & Co | Quinazolinderivat med tyrosin-kinase inhibitorisk aktivitet |
CA2599210A1 (en) * | 2005-02-26 | 2006-08-31 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
GB0504474D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
BRPI0609655A2 (pt) | 2005-03-31 | 2010-03-16 | Agensys Inc | anticorpos e moléculas relacionadas que ligam-se às proteìnas 161p2f10b |
AU2006238930B2 (en) | 2005-04-26 | 2010-12-23 | Pfizer Inc. | P-cadherin antibodies |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
GB0508717D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
GB0508715D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
CN1858040B (zh) * | 2005-05-08 | 2011-04-06 | 中国科学院上海药物研究所 | 5,8-二取代喹唑啉及其制备方法和用途 |
SI1885187T1 (sl) | 2005-05-13 | 2013-12-31 | Novartis Ag | Postopki za zdravljenje raka, rezistentnega na zdravila |
EP2465857B1 (en) | 2005-05-17 | 2014-06-04 | Novartis AG | Methods for synthesizing heterocyclic compounds |
UA93678C2 (ru) | 2005-05-18 | 2011-03-10 | Астразенека Аб | Гетероциклические ингибиторы mek и их применение |
SG154451A1 (en) | 2005-05-23 | 2009-08-28 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1- yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
MX2008000821A (es) | 2005-07-21 | 2008-03-19 | Astrazeneca Ab | Nuevos derivados de piperidina. |
TW200738634A (en) | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
US7566721B2 (en) * | 2005-08-08 | 2009-07-28 | Osi Pharmaceuticals, Inc. | Substituted thienol[2,3-d]pyrimidines as kinase inhibitors |
TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
ES2546069T3 (es) | 2005-09-07 | 2015-09-18 | Amgen Fremont Inc. | Anticuerpos monoclonales humanos para quinasa-1 de tipo receptor de activina (ALK-1) |
WO2007035744A1 (en) | 2005-09-20 | 2007-03-29 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20090239861A1 (en) * | 2005-09-20 | 2009-09-24 | Robert Hugh Bradbury | Quinazoline derivatives as anticancer agents |
US7820683B2 (en) | 2005-09-20 | 2010-10-26 | Astrazeneca Ab | 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer |
EP1939200A4 (en) | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
JPWO2007034881A1 (ja) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
WO2007034882A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
WO2007034917A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規なアデニン化合物 |
GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
WO2007039736A1 (en) | 2005-10-06 | 2007-04-12 | Astrazeneca Ab | Novel compounds |
DK1945631T3 (da) | 2005-10-28 | 2012-10-22 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer |
EP1948179A1 (en) | 2005-11-11 | 2008-07-30 | Boehringer Ingelheim International GmbH | Quinazoline derivatives for the treatment of cancer diseases |
ES2335535T3 (es) | 2005-11-15 | 2010-03-29 | Array Biopharma Inc. | Derivados de n4-fenil-quinazolin-4-amina ycompuestos afines como inhibidores de la tirosina quinasa receptora erbb tipo i para el tratamiento de enfermedades hiperproliferativas. |
AU2006320591B2 (en) | 2005-11-29 | 2010-06-03 | Novartis Ag | Formulations of quinolinones |
WO2007063293A1 (en) * | 2005-12-02 | 2007-06-07 | Astrazeneca Ab | Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase |
AR057960A1 (es) * | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
WO2007063291A1 (en) * | 2005-12-02 | 2007-06-07 | Astrazeneca Ab | 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors |
TW200730512A (en) | 2005-12-12 | 2007-08-16 | Astrazeneca Ab | Novel compounds |
CA2633956C (en) | 2005-12-13 | 2016-12-06 | Olivia Raeber | Binding proteins specific for insulin-like growth factors and uses thereof |
JP2009519308A (ja) | 2005-12-15 | 2009-05-14 | アストラゼネカ・アクチエボラーグ | 呼吸器疾患の処置のための置換ジフェニルエーテル、アミン、スルフィドおよびメタン |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
US20070231298A1 (en) * | 2006-03-31 | 2007-10-04 | Cell Genesys, Inc. | Cytokine-expressing cancer immunotherapy combinations |
TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
EP2021338A1 (en) | 2006-05-09 | 2009-02-11 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
CN102558021A (zh) | 2006-05-26 | 2012-07-11 | 阿斯利康(瑞典)有限公司 | 联芳基或芳基-杂芳基取代的吲哚类化合物 |
CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
DE102006037478A1 (de) | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
KR101438245B1 (ko) * | 2006-08-23 | 2014-09-04 | 쿠도스 파마슈티칼스 리미티드 | Mtor 억제제로서의 2-메틸모르폴린 피리도-, 피라조- 및 피리미도-피리미딘 유도체 |
BRPI0717586A2 (pt) * | 2006-09-18 | 2013-10-29 | Boehringer Ingelheim Int | Método para tratar câncer apresentando mutações do egfr |
CL2007003158A1 (es) * | 2006-11-02 | 2008-05-16 | Astrazeneca Ab | Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion. |
EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
US7799954B2 (en) | 2006-11-17 | 2010-09-21 | Abraxis Bioscience, Llc | Dicarbonyl derivatives and methods of use |
TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
CN101610813A (zh) | 2006-12-19 | 2009-12-23 | 阿斯利康(瑞典)有限公司 | 作为毒蕈碱受体拮抗剂的奎核醇衍生物 |
CL2008000191A1 (es) | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer. |
AU2008212999A1 (en) | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof |
US20080190689A1 (en) * | 2007-02-12 | 2008-08-14 | Ballard Ebbin C | Inserts for engine exhaust systems |
US8148532B2 (en) | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
AR065784A1 (es) | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
JPWO2008114819A1 (ja) | 2007-03-20 | 2010-07-08 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
UA99459C2 (en) | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
DE102007025717A1 (de) | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Arylether-pyridazinonderivate |
DE102007025718A1 (de) | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | Pyridazinonderivate |
DE102007026341A1 (de) | 2007-06-06 | 2008-12-11 | Merck Patent Gmbh | Benzoxazolonderivate |
UA100983C2 (ru) | 2007-07-05 | 2013-02-25 | Астразенека Аб | Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты |
DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
DE102007038957A1 (de) | 2007-08-17 | 2009-02-19 | Merck Patent Gmbh | 6-Thioxo-pyridazinderivate |
DE102007041115A1 (de) | 2007-08-30 | 2009-03-05 | Merck Patent Gmbh | Thiadiazinonderivate |
ES2424745T3 (es) | 2007-09-07 | 2013-10-08 | Agensys, Inc. | Anticuerpos y moléculas relacionadas que se unen a las proteínas 24P4C12 |
KR20100087147A (ko) | 2007-10-04 | 2010-08-03 | 아스트라제네카 아베 | 글루코코르티코이드 활성을 갖는 스테로이드성 [3,2-c]피라졸 화합물 |
RS53552B1 (en) | 2007-10-11 | 2015-02-27 | Astrazeneca Ab | DERIVATI PIROLO [2,3-D] PIRIMIDINA KAO INHIBITORI PROTEIN KINAZE B |
CN101945870B (zh) | 2007-12-19 | 2012-10-03 | 健泰科生物技术公司 | 5-苯氨基咪唑并吡啶和使用方法 |
AU2008339576B2 (en) | 2007-12-21 | 2014-05-22 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Ralpha) |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
WO2009082687A1 (en) | 2007-12-21 | 2009-07-02 | Genentech, Inc. | Azaindolizines and methods of use |
DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
WO2009091939A1 (en) * | 2008-01-18 | 2009-07-23 | Osi Pharmaceuticals, Inc. | Imidazopyrazinol derivatives for the treatment of cancers |
US7855204B2 (en) * | 2008-01-22 | 2010-12-21 | Concert Pharmaceuticals Inc. | Derivatives of gefitinib |
US8609673B2 (en) * | 2008-01-22 | 2013-12-17 | Concert Pharmaceuticals, Inc. | Vandetanib derivatives |
ES2392639T3 (es) | 2008-02-07 | 2012-12-12 | Boehringer Ingelheim International Gmbh | Heterociclos espirocíclicos, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparación |
CA2712990C (en) | 2008-02-28 | 2016-09-27 | Bayard R. Huck | Benzonaphthyridinyl compounds as protein kinase inhibitors and use thereof |
DE102008019907A1 (de) | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | Pyridazinonderivate |
MX2010012442A (es) | 2008-05-13 | 2011-10-11 | Astrazeneca Ab | Sal de fumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-m etilcarbamoilmetil) piperidin-4-il]oxi}quinazolina. |
ES2396613T3 (es) * | 2008-05-19 | 2013-02-22 | OSI Pharmaceuticals, LLC | Imidazopirazinas e imidazotriazinas sustituidas |
RU2509077C2 (ru) | 2008-05-27 | 2014-03-10 | Астразенека Аб | Феноксипиридиниламидные производные и их применение в лечении pde4-опосредованных болезненных состояний |
DE102008025750A1 (de) | 2008-05-29 | 2009-12-03 | Merck Patent Gmbh | Dihydropyrazolderivate |
DE102008028905A1 (de) | 2008-06-18 | 2009-12-24 | Merck Patent Gmbh | 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate |
DE102008029734A1 (de) | 2008-06-23 | 2009-12-24 | Merck Patent Gmbh | Thiazolyl-piperidinderivate |
UY31952A (es) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
WO2010015522A1 (de) | 2008-08-08 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
DE102008037790A1 (de) | 2008-08-14 | 2010-02-18 | Merck Patent Gmbh | Bicyclische Triazolderivate |
DE102008038221A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | 7-Azaindolderivate |
US8211911B2 (en) | 2008-08-19 | 2012-07-03 | Guoqing Paul Chen | Compounds as kinase inhibitors |
US8192738B2 (en) | 2008-09-19 | 2012-06-05 | Medimmune, Llc | Targeted antibodies directed to DLL4 |
JP5836125B2 (ja) | 2008-10-16 | 2015-12-24 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用 |
DE102008052943A1 (de) | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
WO2010067102A1 (en) | 2008-12-09 | 2010-06-17 | Astrazeneca Ab | Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders |
WO2010068861A1 (en) | 2008-12-11 | 2010-06-17 | Axcentua Pharmaceutucals Ab | Crystalline forms of genistein |
US7863325B2 (en) | 2008-12-11 | 2011-01-04 | Axcentua Pharmaceuticals Ab | Crystalline genistein sodium salt dihydrate |
US20100152197A1 (en) | 2008-12-15 | 2010-06-17 | Astrazeneca Ab | (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives |
AU2009333653B2 (en) | 2008-12-17 | 2015-09-10 | Merck Patent Gmbh | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof |
DE102008063667A1 (de) | 2008-12-18 | 2010-07-01 | Merck Patent Gmbh | 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate |
JP2012512871A (ja) | 2008-12-18 | 2012-06-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 三環式アザインドール |
DE102008062826A1 (de) | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
CA2748158A1 (en) | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | Targeted binding agents directed to .alpha.5.beta.1 and uses thereof |
DE102008062825A1 (de) | 2008-12-23 | 2010-06-24 | Merck Patent Gmbh | 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate |
DE102009003954A1 (de) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
DE102009003975A1 (de) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Benzothiazolonderivate |
DE102009004061A1 (de) | 2009-01-08 | 2010-07-15 | Merck Patent Gmbh | Pyridazinonderivate |
KR101733773B1 (ko) | 2009-01-16 | 2017-05-10 | 엑셀리시스, 인코포레이티드 | N-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
RU2683325C2 (ru) | 2009-02-05 | 2019-03-28 | Иммьюноджен, Инк. | Новые производные бензодиазепина |
WO2010089580A1 (en) | 2009-02-06 | 2010-08-12 | Astrazeneca Ab | Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4 |
WO2010090764A1 (en) | 2009-02-09 | 2010-08-12 | Supergen, Inc. | Pyrrolopyrimidinyl axl kinase inhibitors |
WO2010092371A1 (en) | 2009-02-10 | 2010-08-19 | Astrazeneca Ab | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
EP2400990A2 (en) | 2009-02-26 | 2012-01-04 | OSI Pharmaceuticals, LLC | In situ methods for monitoring the emt status of tumor cells in vivo |
EP2401613A2 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010098866A1 (en) | 2009-02-27 | 2010-09-02 | Supergen, Inc. | Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors |
GB0905127D0 (en) | 2009-03-25 | 2009-05-06 | Pharminox Ltd | Novel prodrugs |
UY32520A (es) | 2009-04-03 | 2010-10-29 | Astrazeneca Ab | Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides |
CA2752826A1 (en) | 2009-04-20 | 2010-10-28 | OSI Pharmaceuticals, LLC | Preparation of c-pyrazine-methylamines |
JP2012526138A (ja) * | 2009-05-07 | 2012-10-25 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 副腎皮質癌を治療するためのosi−906の使用 |
US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
US20100317593A1 (en) | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
DK2451445T3 (da) | 2009-07-06 | 2019-06-24 | Boehringer Ingelheim Int | Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens |
AU2010273585B2 (en) | 2009-07-13 | 2015-04-23 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
JP2013500991A (ja) | 2009-07-31 | 2013-01-10 | オーエスアイ・ファーマシューティカルズ,エルエルシー | mTOR阻害剤および血管新生阻害剤併用療法 |
GB0913342D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
JP2013503846A (ja) | 2009-09-01 | 2013-02-04 | ファイザー・インク | ベンズイミダゾール誘導体 |
US20110064670A1 (en) | 2009-09-11 | 2011-03-17 | Genentech, Inc. | Method to identify a patient with an increased likelihood of responding to an anti-cancer agent |
ES2530732T3 (es) | 2009-09-17 | 2015-03-05 | Hoffmann La Roche | Procedimientos de diagnóstico para el cáncer de pulmón |
DE102009043260A1 (de) | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolonderivate |
MX2012003644A (es) | 2009-10-02 | 2012-04-30 | Astrazeneca Ab | Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila. |
DE102009049679A1 (de) | 2009-10-19 | 2011-04-21 | Merck Patent Gmbh | Pyrazolopyrimidinderivate |
WO2011048409A1 (en) | 2009-10-20 | 2011-04-28 | Astrazeneca Ab | Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
US8399460B2 (en) | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
AU2010311321B2 (en) | 2009-10-30 | 2014-11-27 | Prexton Therapeutics S.A. | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
KR20120113709A (ko) | 2009-11-18 | 2012-10-15 | 아스트라제네카 아베 | 벤조이미다졸 화합물 및 그의 용도 |
PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
WO2011068233A1 (en) | 2009-12-03 | 2011-06-09 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazoquinolines which act via toll - like receptors (tlr) |
JP2013513628A (ja) | 2009-12-14 | 2013-04-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | スフィンゴシンキナーゼの阻害薬 |
DE102009058280A1 (de) | 2009-12-14 | 2011-06-16 | Merck Patent Gmbh | Thiazolderivate |
WO2011073521A1 (en) | 2009-12-15 | 2011-06-23 | Petri Salven | Methods for enriching adult-derived endothelial progenitor cells and uses thereof |
WO2011082732A1 (de) | 2009-12-17 | 2011-07-14 | Merck Patent Gmbh | Inhibitoren der sphingosinkinase |
EP2523966B1 (en) | 2010-01-15 | 2017-10-04 | Suzhou Neupharma Co., Ltd | Certain chemical entities, compositions, and methods |
US8198285B2 (en) | 2010-01-19 | 2012-06-12 | Astrazeneca Ab | Pyrazine derivatives |
WO2011095807A1 (en) | 2010-02-07 | 2011-08-11 | Astrazeneca Ab | Combinations of mek and hh inhibitors |
CN105001334A (zh) | 2010-02-10 | 2015-10-28 | 伊缪诺金公司 | Cd20抗体及其用途 |
EP3150610B1 (en) | 2010-02-12 | 2019-07-31 | Pfizer Inc | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
WO2011109572A2 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
CA2783665A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
WO2011114148A1 (en) | 2010-03-17 | 2011-09-22 | Astrazeneca Ab | 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists |
WO2011153224A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
WO2011154677A1 (en) | 2010-06-09 | 2011-12-15 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760 |
GB201009801D0 (en) | 2010-06-11 | 2010-07-21 | Astrazeneca Ab | Compounds 950 |
ES2695899T3 (es) | 2010-06-16 | 2019-01-11 | Univ Pittsburgh Commonwealth Sys Higher Education | Anticuerpos contra endoplasmina y su uso |
CA2805708A1 (en) | 2010-07-19 | 2012-01-26 | F. Hoffmann-La Roche Ag | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
EP2596362A1 (en) | 2010-07-19 | 2013-05-29 | F. Hoffmann-La Roche AG | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
EP3696195B1 (en) | 2010-07-23 | 2024-02-14 | Trustees of Boston University | Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
UY33539A (es) | 2010-08-02 | 2012-02-29 | Astrazeneca Ab | Compuestos químicos alk |
TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
DE102010034699A1 (de) | 2010-08-18 | 2012-02-23 | Merck Patent Gmbh | Pyrimidinderivate |
CN102656179B (zh) | 2010-08-28 | 2015-07-29 | 苏州润新生物科技有限公司 | 蟾蜍灵衍生物、其药物组合物及用途 |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
GB201016442D0 (en) | 2010-09-30 | 2010-11-17 | Pharminox Ltd | Novel acridine derivatives |
CA2813162C (en) | 2010-10-20 | 2015-06-16 | Pfizer Inc. | Pyridine-2- derivatives as smoothened receptor modulators |
DE102010048800A1 (de) | 2010-10-20 | 2012-05-10 | Merck Patent Gmbh | Chinoxalinderivate |
DE102010049595A1 (de) | 2010-10-26 | 2012-04-26 | Merck Patent Gmbh | Chinazolinderivate |
WO2012066336A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
WO2012067269A1 (en) | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Aminoalkoxyphenyl compounds and their use in the treatment of disease |
WO2012066335A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Phenol compounds als toll -like receptor 7 agonists |
WO2012067268A1 (en) | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Cyclic amide compounds and their use in the treatment of disease |
JP5978225B2 (ja) | 2010-12-16 | 2016-08-24 | 大日本住友製薬株式会社 | 治療に有用なイミダゾ[4,5−c]キノリン−1−イル誘導体 |
EP2651943B1 (en) | 2010-12-17 | 2017-03-22 | Sumitomo Dainippon Pharma Co., Ltd. | Purine derivatives |
BR112013015508B1 (pt) | 2010-12-20 | 2022-04-05 | Medimmune Limited | Molécula de anticorpo para il-18 humana, domínio vh isolado e domínio vl isolado, composição, uso de uma molécula de anticorpo ou do domínio vh isolado e do domínio vl isolado, molécula de ácido nucleico isolada, célula hospedeira procariótica recombinante, método para produzir um anticorpo, e método in vitro para medir il-18 em uma amostra de um indivíduo |
WO2012103810A1 (en) | 2011-02-02 | 2012-08-09 | Suzhou Neupharma Co., Ltd | Certain chemical entities, compositions, and methods |
ES2717657T3 (es) | 2011-02-15 | 2019-06-24 | Immunogen Inc | Métodos para la preparación de conjugados |
EP2675793B1 (en) | 2011-02-17 | 2018-08-08 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
CN103534240B (zh) | 2011-02-17 | 2015-12-09 | 癌症疗法Crc私人有限公司 | 选择性fak抑制剂 |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
WO2012142164A1 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii |
US8530470B2 (en) | 2011-04-13 | 2013-09-10 | Astrazeneca Ab | Chromenone derivatives |
DK2699598T3 (en) | 2011-04-19 | 2019-04-23 | Pfizer | COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER |
US9896730B2 (en) | 2011-04-25 | 2018-02-20 | OSI Pharmaceuticals, LLC | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment |
WO2012175991A1 (en) | 2011-06-24 | 2012-12-27 | Pharminox Limited | Fused pentacyclic anti - proliferative compounds |
US20140227293A1 (en) | 2011-06-30 | 2014-08-14 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
WO2013008002A1 (en) | 2011-07-12 | 2013-01-17 | Astrazeneca Ab | N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator |
JP6105578B2 (ja) | 2011-07-21 | 2017-03-29 | トレロ ファーマシューティカルズ, インコーポレイテッド | 複素環式プロテインキナーゼ阻害剤 |
CN105348266B (zh) | 2011-07-27 | 2018-04-10 | 阿斯利康(瑞典)有限公司 | 取代的3‑氯‑n‑[3‑(嘧啶‑2‑基氨基)苯基]丙酰胺或其盐 |
DE102011111400A1 (de) | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
CN107245056A (zh) | 2011-08-26 | 2017-10-13 | 润新生物公司 | 化学实体、组合物及方法 |
WO2013033250A1 (en) | 2011-09-01 | 2013-03-07 | Xiangping Qian | Certain chemical entities, compositions, and methods |
WO2013040515A1 (en) | 2011-09-14 | 2013-03-21 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
WO2013043935A1 (en) | 2011-09-21 | 2013-03-28 | Neupharma, Inc. | Certain chemical entites, compositions, and methods |
SG2014014450A (en) | 2011-09-22 | 2014-09-26 | Pfizer | Pyrrolopyrimidine and purine derivatives |
WO2013045955A1 (en) | 2011-09-29 | 2013-04-04 | The University Of Liverpool | Prevention and/or treatment of cancer and/or cancer metastasis |
WO2013049701A1 (en) | 2011-09-30 | 2013-04-04 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
EP2764025B1 (en) | 2011-10-04 | 2017-11-29 | IGEM Therapeutics Limited | Ige-antibodies against hmw-maa |
MX2014005570A (es) | 2011-11-08 | 2014-05-30 | Pfizer | El uso de anticuerpos anti factor estimulante de la colonia de macrofagos para tratar trastornos inflamatorios. |
US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
WO2013112950A2 (en) | 2012-01-25 | 2013-08-01 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
SG11201404234YA (en) | 2012-01-28 | 2014-08-28 | Merck Patent Gmbh | Triazolo[4,5-d]pyrimidine derivatives |
ES2606637T3 (es) | 2012-02-09 | 2017-03-24 | Merck Patent Gmbh | Derivados de furo [3,2- b]piridina como inhibidores de TBK1 e IKK |
JP6116592B2 (ja) | 2012-02-09 | 2017-04-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Tankおよびparpのインヒビターとしてのテトラヒドロ−キナゾリノン誘導体 |
JP6479476B2 (ja) | 2012-02-21 | 2019-03-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | SykチロシンキナーゼインヒビターおよびGCN2セリンキナーゼインヒビターとしての8−置換2−アミノー[1,2,4]トリアゾロ[1,5−A]ピラジン類 |
CA2865040C (en) | 2012-02-21 | 2020-07-14 | Merck Patent Gmbh | Cyclic diaminopyrimidine derivatives |
CN104114558B (zh) | 2012-02-21 | 2016-10-26 | 默克专利股份公司 | 呋喃并吡啶衍生物 |
WO2013131609A1 (en) | 2012-03-07 | 2013-09-12 | Merck Patent Gmbh | Triazolopyrazine derivatives |
ES2585044T3 (es) | 2012-03-28 | 2016-10-03 | Merck Patent Gmbh | Derivados de pirazinona bicíclicos |
WO2013144532A1 (en) | 2012-03-30 | 2013-10-03 | Astrazeneca Ab | 3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents |
EA201401077A1 (ru) | 2012-04-05 | 2015-02-27 | Ф.Хоффманн-Ля Рош Аг | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
CN109354598A (zh) | 2012-04-29 | 2019-02-19 | 润新生物公司 | 化学个体、药物组合物及癌症治疗方法 |
RS55062B1 (sr) | 2012-05-04 | 2016-12-30 | Merck Patent Gmbh | Pirolotriazinon derivati |
SG11201408161RA (en) | 2012-06-08 | 2015-01-29 | Sutro Biopharma Inc | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
GB201211021D0 (en) | 2012-06-21 | 2012-08-01 | Cancer Rec Tech Ltd | Pharmaceutically active compounds |
US9732161B2 (en) | 2012-06-26 | 2017-08-15 | Sutro Biopharma, Inc. | Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
CN104507957B (zh) | 2012-07-24 | 2018-12-25 | 默克专利股份有限公司 | 用于治疗关节病的羟基他汀衍生物 |
ES2618004T3 (es) | 2012-08-07 | 2017-06-20 | Merck Patent Gmbh | Derivados de piridopirimidina como inhibidores de proteínas quinasas |
ES2773272T3 (es) | 2012-08-08 | 2020-07-10 | Merck Patent Gmbh | Derivados de (aza-)isoquinolinona |
US9238644B2 (en) | 2012-08-17 | 2016-01-19 | Cancer Therapeutics Crc Pty Limited | VEGFR3 inhibitors |
EP2887965A1 (en) | 2012-08-22 | 2015-07-01 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
EP2890402B1 (en) | 2012-08-31 | 2019-04-17 | Sutro Biopharma, Inc. | Modified amino acids comprising an azido group |
WO2014041349A1 (en) | 2012-09-12 | 2014-03-20 | Cancer Therapeutics Crc Pty Ltd | Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors |
WO2014047648A1 (en) | 2012-09-24 | 2014-03-27 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
AU2013324681B2 (en) | 2012-09-26 | 2017-08-10 | Merck Patent Gmbh | Quinazolinone derivatives as PARP inhibitors |
US10253107B2 (en) | 2012-10-26 | 2019-04-09 | The University Of Queensland | Use of endocytosis inhibitors and antibodies for cancer therapy |
JP6304776B2 (ja) | 2012-11-05 | 2018-04-04 | ジーエムディーエックス カンパニー プロプライエタリー リミテッド | 体細胞突然変異生成の原因を判定するための方法 |
US9725421B2 (en) | 2012-11-12 | 2017-08-08 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
MX2015006037A (es) | 2012-11-16 | 2015-08-07 | Merck Patent Gmbh | Derivados de 3-aminociclopentancarboxamida. |
US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
PL3381917T3 (pl) | 2013-01-31 | 2021-12-27 | Bellus Health Cough Inc. | Związki imidazopirydynowe i i ch zastosowania |
US9663475B2 (en) | 2013-02-25 | 2017-05-30 | Merck Patent Gmbh | 2 amino-3,4-dihydrcquinazoline derivatives and the use thereof as cathepsin D inhibitors |
WO2014134483A2 (en) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
EP2961435B1 (en) | 2013-02-28 | 2019-05-01 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
EP2964648B1 (en) | 2013-03-05 | 2016-11-16 | Merck Patent GmbH | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
TR201911151T4 (tr) | 2013-03-14 | 2019-08-21 | Tolero Pharmaceuticals Inc | Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri. |
CN113398147A (zh) | 2013-03-15 | 2021-09-17 | 纽罗森特里亚股份有限公司 | 用于癌症的镁组合物及其用途 |
WO2014161570A1 (en) | 2013-04-03 | 2014-10-09 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
EP3004073A1 (en) | 2013-06-07 | 2016-04-13 | Université catholique de Louvain | 3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases |
WO2014205511A1 (en) | 2013-06-25 | 2014-12-31 | University Of Canberra | Methods and compositions for modulating cancer stem cells |
ES2658039T3 (es) | 2013-07-10 | 2018-03-08 | Sutro Biopharma, Inc. | Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso |
JP6559132B2 (ja) | 2013-08-23 | 2019-08-14 | ニューファーマ, インコーポレイテッド | ある特定の化学的実体、組成物および方法 |
EP3046560B1 (en) | 2013-09-18 | 2021-01-06 | EpiAxis Therapeutics Pty Ltd | Stem cell modulation ii |
US20160298197A1 (en) | 2013-10-01 | 2016-10-13 | Queensland University Of Technology | Kits and methods for diagnosis, screening, treatment and disease monitoring |
JP6946000B2 (ja) | 2013-10-04 | 2021-10-06 | アプトース バイオサイエンシーズ, インコーポレイテッド | がんの治療用組成物及び方法 |
EP3055298B1 (en) | 2013-10-11 | 2020-04-29 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
GB201321146D0 (en) * | 2013-11-29 | 2014-01-15 | Cancer Rec Tech Ltd | Quinazoline compounds |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
CN104829542B (zh) * | 2014-02-10 | 2018-02-02 | 中国科学院上海药物研究所 | 苯胺嘧啶类化合物、其制备方法和医药用途 |
GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
ES2727374T3 (es) | 2014-04-04 | 2019-10-15 | Crown Bioscience Inc Taicang | Gen de fusión HNF4G-RSPO2 |
WO2015155624A1 (en) | 2014-04-10 | 2015-10-15 | Pfizer Inc. | Dihydropyrrolopyrimidine derivatives |
MA39926B1 (fr) | 2014-04-30 | 2019-12-31 | Pfizer | Dérivés de dihétérocycle liés à cycloalkyle |
WO2016001789A1 (en) | 2014-06-30 | 2016-01-07 | Pfizer Inc. | Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer |
US10934360B2 (en) | 2014-07-31 | 2021-03-02 | The Hong Kong University Of Science And Technology | Human monoclonal antibodies against EPHA4 and their use |
EP3185858A4 (en) | 2014-08-25 | 2017-12-27 | University of Canberra | Compositions for modulating cancer stem cells and uses therefor |
US20190072557A1 (en) | 2014-11-17 | 2019-03-07 | The University Of Queensland | Glycoprotein biomarkers for esophageal adenocarcinoma and barrett's esophagus and uses thereof |
EP3233829B1 (en) | 2014-12-18 | 2019-08-14 | Pfizer Inc | Pyrimidine and triazine derivatives and their use as axl inhibitors |
MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
GB201501870D0 (en) | 2015-02-04 | 2015-03-18 | Cancer Rec Tech Ltd | Autotaxin inhibitors |
GB201502020D0 (en) | 2015-02-06 | 2015-03-25 | Cancer Rec Tech Ltd | Autotaxin inhibitory compounds |
US10947201B2 (en) | 2015-02-17 | 2021-03-16 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
AU2016252609B2 (en) | 2015-04-20 | 2022-06-30 | Sumitomo Pharma Oncology, Inc. | Predicting response to alvocidib by mitochondrial profiling |
CN107709344B (zh) | 2015-05-01 | 2022-07-15 | 共晶制药股份有限公司 | 用于治疗黄病毒科病毒和癌症的核苷类似物 |
PT3298021T (pt) | 2015-05-18 | 2019-08-05 | Tolero Pharmaceuticals Inc | Pró-fármacos de alvocidib possuindo biodisponibilidade aumentada |
GB201510019D0 (en) | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
JP7083497B2 (ja) | 2015-08-03 | 2022-06-13 | スミトモ ファーマ オンコロジー, インコーポレイテッド | がんの処置のための併用療法 |
EP3957637B1 (en) | 2015-08-04 | 2023-06-28 | Aucentra Therapeutics Pty Ltd | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds |
WO2017031551A1 (en) | 2015-08-26 | 2017-03-02 | Gmdx Co Pty Ltd | Methods of detecting cancer recurrence |
GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
GB201519568D0 (en) | 2015-11-05 | 2015-12-23 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
US20180371551A1 (en) | 2015-12-03 | 2018-12-27 | Agios Pharmaceuticals, Inc. | Mat2a inhibitors for treating mtap null cancer |
KR20180104106A (ko) | 2016-01-27 | 2018-09-19 | 서트로 바이오파마, 인크. | anti-CD74 항체 접합체, anti-CD74 항체 접합체를 포함하는 조성물 및 anti-CD74 항체 접합체의 이용 방법 |
CN108883155A (zh) | 2016-02-01 | 2018-11-23 | 堪培拉大学 | 蛋白化合物及其用途 |
GB201604182D0 (en) | 2016-03-11 | 2016-04-27 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
MA43733A (fr) | 2016-03-21 | 2018-11-28 | Astrazeneca Ab | Composés cinnolin-4-amine et leur utilisation pour traiter le cancer |
CA3015953A1 (en) | 2016-04-07 | 2017-10-12 | Astrazeneca Ab | N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancer |
DK3442535T3 (da) | 2016-04-15 | 2022-09-05 | Cancer Research Tech Ltd | Heterocykliske stoffer som as ret-kinase-hæmmere |
GB2554333A (en) | 2016-04-26 | 2018-04-04 | Big Dna Ltd | Combination therapy |
GB201608227D0 (en) | 2016-05-11 | 2016-06-22 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
DK3490565T3 (da) | 2016-07-29 | 2022-07-11 | Rapt Therapeutics Inc | Azetidinderivater som chemokinreceptormodulatorer og anvendelser deraf |
EP4006035B1 (en) | 2016-08-15 | 2023-11-22 | Neupharma, Inc. | Quinazoline derivatives as tyrosine kinase inhibitors for the treatment of cancer |
AU2017321973A1 (en) | 2016-09-02 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating B cell disorders |
JP7118974B2 (ja) | 2016-09-22 | 2022-08-16 | キャンサー・リサーチ・テクノロジー・リミテッド | ピリミジノン誘導体の調製および使用 |
GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
JP7071392B2 (ja) | 2016-12-05 | 2022-05-18 | アプロス セラピューティクス, インコーポレイテッド | 酸性基を含有するピリミジン化合物 |
US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
AU2017379847B2 (en) | 2016-12-19 | 2022-05-26 | Sumitomo Pharma Oncology, Inc. | Profiling peptides and methods for sensitivity profiling |
PE20191474A1 (es) | 2016-12-20 | 2019-10-16 | Astrazeneca Ab | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer |
AU2018214431B2 (en) | 2017-02-01 | 2021-07-29 | Aucentra Therapeutics Pty Ltd | Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo [1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents |
EP3592730B1 (en) | 2017-03-09 | 2021-08-04 | Truly Translational Sweden AB | Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease |
JOP20190209A1 (ar) | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
GB201704325D0 (en) | 2017-03-17 | 2017-05-03 | Argonaut Therapeutics Ltd | Compounds |
GB201705971D0 (en) | 2017-04-13 | 2017-05-31 | Cancer Res Tech Ltd | Inhibitor compounds |
CN108864079B (zh) | 2017-05-15 | 2021-04-09 | 深圳福沃药业有限公司 | 一种三嗪化合物及其药学上可接受的盐 |
WO2018215798A1 (en) | 2017-05-26 | 2018-11-29 | Cancer Research Technology Limited | 2-quinolone derived inhibitors of bcl6 |
WO2018220101A1 (en) | 2017-05-31 | 2018-12-06 | Truly Translational Sweden Ab | A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy |
US11319304B2 (en) * | 2017-06-28 | 2022-05-03 | Vanderbilt University | Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
EP3648797A1 (en) | 2017-07-05 | 2020-05-13 | EPOS-Iasis Research and Development, Ltd | Multifunctional conjugates |
EP3658588A1 (en) | 2017-07-26 | 2020-06-03 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
WO2019025099A1 (en) | 2017-08-01 | 2019-02-07 | Merck Patent Gmbh | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS |
US11447505B1 (en) | 2017-08-18 | 2022-09-20 | Cancer Research Technology Limited | Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer |
TW201920123A (zh) | 2017-08-21 | 2019-06-01 | 德商馬克專利公司 | 作為腺苷受體拮抗劑之喹㗁啉衍生物 |
BR112020003594A2 (pt) | 2017-08-21 | 2020-09-01 | Merck Patent Gmbh | derivados de benzimidazol como antagonistas de receptor de adenosina |
US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
US10596270B2 (en) | 2017-09-18 | 2020-03-24 | Sutro Biopharma, Inc. | Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates |
CN111344293A (zh) | 2017-09-20 | 2020-06-26 | 阿斯利康(瑞典)有限公司 | 1,3-二氢咪唑并[4,5-c]噌啉-2-酮化合物及其在治疗癌症中的用途 |
TWI702205B (zh) | 2017-10-06 | 2020-08-21 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | 表皮生長因子受體抑制劑 |
US20200237766A1 (en) | 2017-10-13 | 2020-07-30 | Tolero Pharmaceuticals, Inc. | Pkm2 activators in combination with reactive oxygen species for treatment of cancer |
BR112020009055A2 (pt) | 2017-11-06 | 2020-11-03 | Rapt Therapeutics, Inc. | moduladores de receptor de quimiocina para tratamento de câncer positivo para vírus epstein barr |
FI3488868T3 (fi) | 2017-11-23 | 2023-10-20 | Medac Ges Fuer Klinische Spezialpraeparate Mbh | Suun kautta annettava sulfasalatsiinia ja/tai sulfasalatsiinin orgaanista suolaa sisältävä farmaseuttinen koostumus, valmistusmenetelmä ja käyttö |
EP3489222A1 (en) | 2017-11-23 | 2019-05-29 | medac Gesellschaft für klinische Spezialpräparate mbH | Sulfasalazine salts, production processes and uses |
CA3087805A1 (en) | 2018-01-15 | 2019-07-18 | Aucentra Holdings Pty Ltd | 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents |
GB201801128D0 (en) | 2018-01-24 | 2018-03-07 | Univ Oxford Innovation Ltd | Compounds |
MX2020007812A (es) | 2018-01-26 | 2020-11-24 | Rapt Therapeutics Inc | Moduladores del receptor de quimiocina y usos de los mismos. |
CA3090528A1 (en) | 2018-02-08 | 2019-08-15 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
WO2019175093A1 (en) | 2018-03-12 | 2019-09-19 | Astrazeneca Ab | Method for treating lung cancer |
PT3774817T (pt) | 2018-04-13 | 2023-03-09 | The Institute Of Cancer Res Royal Cancer Hospital | Inibidores de bcl6 |
JP7427655B2 (ja) | 2018-04-27 | 2024-02-05 | スプルース バイオサイエンシーズ,インク. | 精巣副腎残存腫瘍および卵巣副腎残存腫瘍を処置するための方法 |
US10857153B2 (en) | 2018-06-04 | 2020-12-08 | Apros Therapeutics, Inc. | Pyrimidine compounds containing acidic groups |
GB201809102D0 (en) | 2018-06-04 | 2018-07-18 | Univ Oxford Innovation Ltd | Compounds |
JP2021527051A (ja) | 2018-06-05 | 2021-10-11 | ラプト・セラピューティクス・インコーポレイテッド | ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用 |
GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
KR20210038906A (ko) | 2018-07-26 | 2021-04-08 | 스미토모 다이니폰 파마 온콜로지, 인크. | 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제 |
JP2022500454A (ja) | 2018-09-17 | 2022-01-04 | ストロ バイオファーマ インコーポレーテッド | 抗葉酸受容体抗体コンジュゲートによる併用療法 |
PT3853220T (pt) | 2018-09-18 | 2024-02-22 | Hoffmann La Roche | Derivados de quinazolina enquanto agentes antitumorais |
WO2020068600A1 (en) | 2018-09-24 | 2020-04-02 | Rapt Therapeutics, Inc. | Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof |
JP7473544B2 (ja) | 2018-10-25 | 2024-04-23 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | アデノシン受容体アンタゴニストとしての5-アザインダゾール誘導体 |
CA3117512A1 (en) | 2018-10-25 | 2020-04-30 | Merck Patent Gmbh | 5-azaindazole derivatives as adenosine receptor antagonists |
GB201819126D0 (en) | 2018-11-23 | 2019-01-09 | Cancer Research Tech Ltd | Inhibitor compounds |
KR20210099066A (ko) | 2018-12-04 | 2021-08-11 | 스미토모 다이니폰 파마 온콜로지, 인크. | 암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체 |
EP3960858A4 (en) | 2018-12-25 | 2023-02-15 | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences | SMALL RNA DRUG USED TO PREVENT AND TREAT INFLAMMATION-RELATED DISEASES AND COMBINATIONS THEREOF |
AR117844A1 (es) | 2019-01-22 | 2021-09-01 | Merck Patent Gmbh | Derivados de tiazolopiridina como antagonistas del receptor de adenosina |
WO2020167990A1 (en) | 2019-02-12 | 2020-08-20 | Tolero Pharmaceuticals, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
JP2022524759A (ja) | 2019-03-07 | 2022-05-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Shp2アンタゴニストとしてのカルボキサミド-ピリミジン誘導体 |
JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置 |
MX2021011289A (es) | 2019-03-22 | 2021-11-03 | Sumitomo Pharma Oncology Inc | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. |
CN111747950B (zh) | 2019-03-29 | 2024-01-23 | 深圳福沃药业有限公司 | 用于治疗癌症的嘧啶衍生物 |
WO2020201773A1 (en) | 2019-04-05 | 2020-10-08 | Storm Therapeutics Ltd | Mettl3 inhibitory compounds |
WO2020210384A1 (en) | 2019-04-08 | 2020-10-15 | Merck Patent Gmbh | Pyrimidinone derivatives as shp2 antagonists |
GB201905328D0 (en) | 2019-04-15 | 2019-05-29 | Azeria Therapeutics Ltd | Inhibitor compounds |
US20220362394A1 (en) | 2019-05-03 | 2022-11-17 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
GB201908885D0 (en) | 2019-06-20 | 2019-08-07 | Storm Therapeutics Ltd | Therapeutic compounds |
JP2022545930A (ja) | 2019-08-31 | 2022-11-01 | 上海奕拓醫藥科技有限責任公司 | Fgfr阻害剤とするピラゾール類誘導体及びその調製方法 |
TW202120501A (zh) | 2019-09-20 | 2021-06-01 | 美商愛德亞生物科學公司 | 作為parg抑制劑之4-取代的吲哚及吲唑磺醯胺衍生物 |
GB201913988D0 (en) | 2019-09-27 | 2019-11-13 | Celleron Therapeutics Ltd | Novel treatment |
GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
GB201915829D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
GB201915828D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
GB201915831D0 (en) | 2019-10-31 | 2019-12-18 | Cancer Research Tech Ltd | Compounds, compositions and therapeutic uses thereof |
CA3162166A1 (en) | 2019-12-02 | 2021-06-10 | Storm Therapeutics Limited | Polyheterocyclic compounds as mettl3 inhibitors |
WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
US20230095053A1 (en) | 2020-03-03 | 2023-03-30 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
GB202004960D0 (en) | 2020-04-03 | 2020-05-20 | Kinsenus Ltd | Inhibitor compounds |
GB202012969D0 (en) | 2020-08-19 | 2020-09-30 | Univ Of Oxford | Inhibitor compounds |
WO2022074379A1 (en) | 2020-10-06 | 2022-04-14 | Storm Therapeutics Limited | Mettl3 inhibitory compounds |
WO2022074391A1 (en) | 2020-10-08 | 2022-04-14 | Storm Therapeutics Limited | Compounds inhibitors of mettl3 |
EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
GB202102895D0 (en) | 2021-03-01 | 2021-04-14 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
WO2022197641A1 (en) | 2021-03-15 | 2022-09-22 | Rapt Therapeutics, Inc. | 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases |
KR20240004659A (ko) | 2021-04-30 | 2024-01-11 | 셀진 코포레이션 | 감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법 |
JP2024517872A (ja) | 2021-05-03 | 2024-04-23 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | HER2を標的にするFc抗原結合性フラグメント-薬物抱合体 |
KR20220156448A (ko) | 2021-05-17 | 2022-11-25 | 에이치케이이노엔 주식회사 | 벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
CN117999101A (zh) | 2021-05-25 | 2024-05-07 | 默克专利股份公司 | 靶向EGFR的Fc抗原结合片段-药物缀合物 |
GB202107907D0 (en) | 2021-06-02 | 2021-07-14 | Storm Therapeutics Ltd | Combination therapies |
GB202108383D0 (en) | 2021-06-11 | 2021-07-28 | Argonaut Therapeutics Ltd | Compounds useful in the treatment or prevention of a prmt5-mediated disorder |
AU2022359801A1 (en) | 2021-10-04 | 2024-02-01 | Forx Therapeutics Ag | Parg inhibitory compounds |
WO2023057394A1 (en) | 2021-10-04 | 2023-04-13 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
WO2023131690A1 (en) | 2022-01-10 | 2023-07-13 | Merck Patent Gmbh | Substituted heterocycles as hset inhibitors |
GB202202199D0 (en) | 2022-02-18 | 2022-04-06 | Cancer Research Tech Ltd | Compounds |
WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
WO2023186881A1 (en) | 2022-03-29 | 2023-10-05 | Baden-Württemberg Stiftung Ggmbh | P38 map kinase inhibitors for use in the treatment of colorectal cancer |
GB202204935D0 (en) | 2022-04-04 | 2022-05-18 | Cambridge Entpr Ltd | Nanoparticles |
US20230322741A1 (en) | 2022-04-06 | 2023-10-12 | Rapt Therapeutics, Inc. | Chemokine receptor modulators and uses thereof |
GB202209404D0 (en) | 2022-06-27 | 2022-08-10 | Univ Of Sussex | Compounds |
US20240058465A1 (en) | 2022-06-30 | 2024-02-22 | Sutro Biopharma, Inc. | Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates |
WO2024030825A1 (en) | 2022-08-01 | 2024-02-08 | Neupharma, Inc | Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate |
GB202213167D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
GB202213163D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
GB202213164D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
GB202213166D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
GB202213162D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Prodrugs |
WO2024074497A1 (en) | 2022-10-03 | 2024-04-11 | Forx Therapeutics Ag | Parg inhibitory compound |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3266990A (en) * | 1963-09-24 | 1966-08-16 | Warner Lambert Pharmaceutical | Derivatives of quinazoline |
JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
US4343940A (en) * | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
GB2160201B (en) * | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
EP0326307B1 (en) * | 1988-01-23 | 1994-08-17 | Kyowa Hakko Kogyo Co., Ltd. | Novel pyridazinone derivatives and pharmaceutical preparations containing them |
IL89029A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
US5411963A (en) * | 1988-01-29 | 1995-05-02 | Dowelanco | Quinazoline derivatives |
EP0572437B1 (en) * | 1991-02-20 | 1995-04-26 | Pfizer Inc. | 2,4-diaminoquinazolines derivatives for enhancing antitumor activity |
DE4105518A1 (de) | 1991-02-22 | 1992-08-27 | Basf Ag | Sulfonylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung |
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
AU658646B2 (en) * | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
NZ243082A (en) * | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
DE4208254A1 (de) * | 1992-03-14 | 1993-09-16 | Hoechst Ag | Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid |
US5270466A (en) * | 1992-06-11 | 1993-12-14 | American Cyanamid Company | Substituted quinazoline fungicidal agents |
US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
GB9323290D0 (en) * | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
DE4309613C2 (de) | 1993-03-24 | 1996-10-17 | Bfi Entsorgungstech | Vorrichtung zum Verteilen fester Abfallmaterialien auf einem Transportband |
GB9314893D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
GB9314884D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
US5661147A (en) * | 1993-09-03 | 1997-08-26 | Kyowa Hakko Kogyo Co., Ltd. | Imidazoquinazoline derivatives |
GB9325217D0 (en) * | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
IL112248A0 (en) * | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
RU2137762C1 (ru) * | 1994-02-23 | 1999-09-20 | Пфайзер Инк. | 4-гетероциклил-замещенные производные хиназолина, фармацевтическая композиция |
AU2096895A (en) * | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
ATE159257T1 (de) * | 1994-05-03 | 1997-11-15 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer wirkung |
DE19503151A1 (de) * | 1995-02-01 | 1996-08-08 | Thomae Gmbh Dr K | Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
TW414798B (en) * | 1994-09-07 | 2000-12-11 | Thomae Gmbh Dr K | Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation |
GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
TW321649B (ja) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
AU5108196A (en) * | 1995-03-20 | 1996-10-08 | Dr. Karl Thomae Gmbh | Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation |
ES2332984T3 (es) * | 1995-03-30 | 2010-02-16 | Pfizer Products Inc. | Derivados de quinazolinas. |
DE19513330A1 (de) * | 1995-04-03 | 1996-10-10 | Schering Ag | Neues Verfahren zur Herstellung von Nucleosiden |
DK0819129T3 (da) * | 1995-04-03 | 2000-10-23 | Novartis Ag | Pyrazolderivater og fremgangsmåde til deres fremstilling |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
EP0824525B1 (en) * | 1995-04-27 | 2001-06-13 | AstraZeneca AB | Quinazoline derivatives |
IL117923A (en) * | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
AU716993B2 (en) * | 1995-05-12 | 2000-03-16 | Neurogen Corporation | Novel deazapurine derivatives; a new class of CRF1 specific ligands |
DE69618587T2 (de) * | 1995-06-07 | 2002-08-29 | Sugen Inc | Chinazoline und pharmazeutische zusammensetzungen |
EP0831829B1 (en) * | 1995-06-07 | 2003-08-20 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
DK0836605T3 (da) * | 1995-07-06 | 2002-05-13 | Novartis Ag | Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling |
GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
AR004010A1 (es) * | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
GB9520822D0 (en) * | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
ES2159760T3 (es) * | 1995-11-14 | 2001-10-16 | Pharmacia & Upjohn Spa | Derivados de aril purina y piridopirimidina y de heteroaril purina y piridopirimidina. |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
US5760041A (en) * | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
EP0837063A1 (en) * | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
-
1996
- 1996-11-25 GB GBGB9624482.7A patent/GB9624482D0/en active Pending
- 1996-12-13 AU AU11061/97A patent/AU712370B2/en not_active Ceased
- 1996-12-13 RU RU98113300/04A patent/RU2194701C2/ru not_active IP Right Cessation
- 1996-12-13 TR TR1998/01115T patent/TR199801115T2/xx unknown
- 1996-12-13 DK DK96941787T patent/DK0873319T3/da active
- 1996-12-13 NZ NZ324007A patent/NZ324007A/xx not_active IP Right Cessation
- 1996-12-13 SI SI9630354T patent/SI0873319T1/xx unknown
- 1996-12-13 PT PT96941787T patent/PT873319E/pt unknown
- 1996-12-13 PL PL327310A patent/PL192309B1/pl not_active IP Right Cessation
- 1996-12-13 JP JP52256897A patent/JP4291413B2/ja not_active Expired - Fee Related
- 1996-12-13 BR BR9612043-6A patent/BR9612043A/pt not_active IP Right Cessation
- 1996-12-13 CA CA002237005A patent/CA2237005C/en not_active Expired - Fee Related
- 1996-12-13 SK SK828-98A patent/SK282443B6/sk not_active IP Right Cessation
- 1996-12-13 WO PCT/GB1996/003075 patent/WO1997022596A1/en not_active Application Discontinuation
- 1996-12-13 HU HU9901243A patent/HUP9901243A3/hu unknown
- 1996-12-13 ES ES96941787T patent/ES2162656T3/es not_active Expired - Lifetime
- 1996-12-13 DE DE69614147T patent/DE69614147T2/de not_active Expired - Lifetime
- 1996-12-13 CZ CZ19981882A patent/CZ291100B6/cs not_active IP Right Cessation
- 1996-12-13 IL IL12492596A patent/IL124925A0/xx not_active IP Right Cessation
- 1996-12-13 KR KR1019980704613A patent/KR100530311B1/ko not_active IP Right Cessation
- 1996-12-13 AT AT96941787T patent/ATE203524T1/de active
- 1996-12-13 EP EP96941787A patent/EP0873319B1/en not_active Expired - Lifetime
- 1996-12-13 CN CNB961991100A patent/CN1133625C/zh not_active Expired - Fee Related
- 1996-12-17 US US08/768,887 patent/US5962458A/en not_active Expired - Lifetime
- 1996-12-17 MY MYPI96005309A patent/MY132405A/en unknown
- 1996-12-17 TW TW085115569A patent/TW411274B/zh not_active IP Right Cessation
-
1998
- 1998-05-28 MX MX9804247A patent/MX9804247A/es unknown
- 1998-06-17 NO NO19982784A patent/NO311358B1/no not_active IP Right Cessation
- 1998-12-02 US US09/203,764 patent/US6071921A/en not_active Expired - Lifetime
-
2000
- 2000-02-09 US US09/500,470 patent/US6258951B1/en not_active Expired - Lifetime
-
2001
- 2001-06-11 US US09/877,005 patent/US6362336B1/en not_active Expired - Lifetime
- 2001-10-19 GR GR20010401823T patent/GR3036954T3/el unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003073356A (ja) * | 2001-08-30 | 2003-03-12 | Koei Chem Co Ltd | メチルヒドロキシアルキルピリジン類の製造方法 |
JPWO2004018430A1 (ja) * | 2002-08-23 | 2005-12-08 | 麒麟麦酒株式会社 | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
JP2007518824A (ja) * | 2004-01-23 | 2007-07-12 | アムゲン インコーポレイテッド | 化合物及び使用方法 |
JP4932495B2 (ja) * | 2004-01-23 | 2012-05-16 | アムゲン インコーポレイテッド | 化合物及び使用方法 |
WO2005080377A1 (ja) * | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
JP2017526668A (ja) * | 2014-08-11 | 2017-09-14 | 石薬集団中奇制薬技術(石家庄)有限公司 | キナゾリン誘導体 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4291413B2 (ja) | キナゾリン誘導体 | |
KR100567649B1 (ko) | 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체 | |
EP0912557B1 (en) | Oxindole derivatives | |
JP5710931B2 (ja) | 血管形成阻害剤としてのキナゾリン誘導体 | |
EP1005470B1 (en) | Oxindolylquinazoline derivatives as angiogenesis inhibitors | |
EP0888310B1 (en) | Cinnoline derivatives and use as medicine | |
EP0880508B1 (en) | Quinazoline derivatives as vegf inhibitors | |
JP2000517291A (ja) | 4―アニリノキナゾリン誘導体 | |
JP2009007364A (ja) | キナゾリン誘導体 | |
UA64704C2 (en) | Quinazoline derivatives, a method for preparing thereof (variants), a pharmaceutical composition and a method for obtaining an antiangiogenic effect and/or effect of vascular permeability | |
KR20050019936A (ko) | 퀴나졸린 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031201 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20031201 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050606 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20050606 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080115 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080118 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080118 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080411 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080526 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080509 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080616 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080604 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080714 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080714 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090324 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090403 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120410 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120410 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130410 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |